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ABSTRACT 
Several studies have shown that epigenetic mechanisms, as microRNAs (miRs) 
expression and gene methylation are involved in cancer, by regulating cell 
proliferation, apoptosis and angiogenesis. Accordingly, epigenetic changes occur 
from early stages and accumulate during cancer progression, by contributing to 
cancer development and progression. 
Since tumour specific genetic and epigenetic alterations can be detected not only 
in cancer tissues but also in circulating serum or plasma cell-free DNA (cfDNA), 
this method is considered promising for improving non-invasive cancer detection 
and monitoring.  
The present work includes three papers presenting genetic and epigenetic changes 
that could contribute to the identification of new non-invasive cancer biomarkers. 
The aim of first work was to compare the status of KRAS mutation and SEPT9 
methylation between the primary tumors and matched plasma samples in patients 
affected by colorectal cancer (CRC). 
KRAS mutations and SEPT9 promoter methylation resulted present in 34.1% 
(29/85) and in 95.3% (81/85) of the primary tumour tissue samples. Patients with 
both genetic and epigenetic alterations in tissue specimens (31.8%, 27/85) were 
considered for further analyses on cfDNA. In 4 primary tumours with KRAS 
mutations, identical mutations were not observed in the corresponding plasma 
samples. The median methylation rate in tumour tissues and plasma samples was 
64.5% (12.2-99.8%) and 14.5% (0-45.5%), respectively. The median KRAS 
mutation load (for matched mutations) was 33.6% (1.2-86%) in tissues and 4% (0-
17%) in plasma samples. A statistically significant correlation was found between 
tissue and plasma SEPT9 methylation rate (r=0.41, p=0.035), whereas no 
association was found between tissue and plasma KRAS mutation load (r=0.09, 
p=0.65). 
These data show a discrepancy in epigenetic versus genetic alterations detectable 
in cfDNA as markers for tumour detection. Many factors could affect the mutant 
cfDNA analysis including the sensitivity of the detection method and the presence 
of tumour clonal heterogeneity. 
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The second line of research has focused on patients affected by epithelial ovarian 
cancer (EOC). Serum levels of miR-199a and miR-125b were found to be 
significantly higher in EOC patients compared to healthy controls (p=0.007 and 
p=0.002, respectively). A statistically significant correlation was found between 
miR-199a and miR-125b expression levels (r=0.38, p=0.03). The ROC curve 
analysis of the diagnostic performance on healthy controls and EOC patients 
revealed that HE4 had a significantly higher area under the curve (AUC: 0.90) 
when compared to CA125 (AUC: 0.85), miR-199a (AUC: 0.70) and miR-125b 
(AUC: 0.67). Despite the low specificity, mainly in pre-menopausal women, 
CA125 and HE4 seem to have better diagnostic performance compared to miRs 
investigated. 
The third line of research has focused on investigate in human endometrial cancer 
(EC) the expression of miR-186, miR-222, miR-223 and miR-204. 
Serum levels of miR-186, miR-222 and miR-223 resulted significantly up-
regulated in patients compared to healthy controls (p=0.004, p=0.002 and 
p<0.0001). Contrarily, miR-204 resulted significantly down-regulated in EC 
patients compared to healthy controls (p<0.0001). A positive significant 
correlation was observed between miR-186 and both miR-222 (r=0.71, p<0.0001) 
and miR-223 (r=0.64, p<0.0001) as well also between miR-222 and miR-223 
(r=0.57, p<0.0001). The AUCs for the selected miRs ranged from 0.70 to 0.87, 
significantly higher than for CA125 (0.59). 
Our results confirm that these miRs are implicated in EC and hold promise as a 
novel blood-based biomarker for the diagnosis. 
In conclusion, our results indicate that circulating nucleic acids are a potentially 
promising source of tumor-specific biomarkers in patients affected by different 
solid cancer. Accordingly, we have demonstrated that some circulating tumour-
specific biomarkers can be detected at any time during the course of the disease 
and once detected indicate that a tumour is probably present. 
The biggest challenge remains to standardize the methodologies including sample 
storage and DNA or miRs extraction to translate the quantitation of circulating 
epigenetic biomarkers into a clinical routine for cancer diagnosis and prognosis 
prediction. 
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RIASSUNTO 
Recenti studi hanno dimostrato che cambiamenti epigenetici, quali ad esempio 
alterata espressione di microRNA (miR) o deregolazione nella metilazione di 
promotori, sono coinvolti nei processi di cancerogenesi in quanto eventi chiave 
nella regolazione del ciclo cellulare, nell'apoptosi o nell'angiogenesi. 
Le alterazioni epigenetiche sono eventi precoci nello sviluppo del tumore e 
accompagnano l'intero processo di formazione neoplastica. 
È possibile studiare le alterazioni epigenetiche non solo a livello tissutale, ma 
anche nei liquidi biologici quali ad esempio il sangue. 
Lo studio di marcatori tumorali nel sangue può essere un potente strumento per 
studiare la dinamicità tumorale, tuttavia, ad oggi, poche molecole hanno una 
sensibilità e specificità tali da essere usate nella pratica clinica. 
Il presente lavoro di tesi include tre studi volti ad analizzare i cambiamenti 
genetici ed epigenetici circolanti in pazienti affetti da tumori solidi, al fine di 
identificare nuovi biomarcatori diagnostici, misurabili in modo non invasivo. 
Nel primo studio abbiamo analizzato lo stato di mutazione del gene KRAS e lo 
stato di metilazione del promotore del gene SEPT9 in tessuto tumorale primario e 
in campioni di plasma ottenuti da pazienti affetti da cancro al colon-retto (CRC).  
Le mutazioni di KRAS sono risultate presenti nel 34.1% (29/85) dei campioni 
tissutali, mentre l'alterato stato di metilazione del promotore del gene SEPT9 nel 
95.3% (81/85). 
I pazienti che presentavano entrambe le alterazioni (31.8%, 27/85) nel tessuto, 
sono stati selezionati per analizzarne il plasma. 
La mediana del tasso di metilazione nei tessuti tumorali e nei campioni di plasma 
è stata 64,5% (12,2-99,8%) e 14,5% (0-45,5%), rispettivamente. 
La mediana del carico di mutazione di KRAS è stata del 33,6% (1,2-86%) nei 
tessuti e del 4% (0-17%) nei campioni di plasma. Una correlazione statisticamente 
significativa è stata osservata tra il tasso di metilazione di SEPT9 nel tessuto ed il 
tasso di metilazione misurato nel plasma (r=0.41, p=0.035), mentre non è stata 
trovata alcuna associazione tra il carico mutazionale del gene KRAS in tessuto e 
plasma (r=0.09, p=0.65). 
GENETIC AND EPIGENETIC ALTERATIONS AS SERUM MARKERS FOR CANCER DETECTION Marco Benati 
 
10 
 
Questi dati mostrano una discrepanza nella rilevabilità delle alterazioni genetiche 
ed epigenetiche nel plasma. Molti fattori possono influenzare l'analisi del DNA 
circolante inclusa la sensibilità del metodo di rilevazione e la presenza di 
eterogeneità clonale della massa tumorale. 
La seconda linea di ricerca ha riguardato il tumore epiteliale all'ovaio (EOC). 
I livelli sierici di miR-199a e miR-125b sono risultati significativamente più 
elevati nelle pazienti con tumore rispetto ai controlli sani (p=0.007 e p=0.002, 
rispettivamente). Una correlazione statisticamente significativa, anche se 
marginalmente, è stata trovata tra i livelli di espressione del miR-199a e miR-
125b (r=0.38, p=0.03). L'analisi della curva ROC, volta ad analizzare le 
performance diagnostiche dei miR studiati, ha rivelato che HE4 presenta un'area 
sotto la curva significativamente più alta (AUC: 0.90) rispetto a quella del CA125 
(AUC: 0.85), del miR-199a (AUC: 0.70) e del miR-125b (AUC: 0.67). 
Nonostante la bassa specificità, soprattutto nelle donne in pre-menopausa, CA125 
e HE4 sembrano quindi avere una migliore performance diagnostica rispetto ai 
miR esaminati nel nostro studio. 
La terza linea di ricerca ha riguardato lo studio dell'espressione di 4 miR (miR-
186, miR-222, miR-223 e miR-204) nel siero di pazienti affette da tumore 
all'endometrio, al fine di analizzarne la performance diagnostica. 
I livelli sierici di miR-186, miR-222 e miR-223 sono risultati significativamente 
più alti (p=0.004, p=0.002 e p<0.0001) e l'espressione di miR-204 è risultata 
significativamente più bassa nelle donne affette da neoplasia rispetto ai controlli 
sani (p<0.0001). È stata inoltre osservata una correlazione statisticamente 
significativa tra miR-186 e miR-222 (r=0.71, p<0.0001) e tra miR-186 e miR-223 
(r=0.64, p<0.0001), così come tra miR-222 e miR-223 (r=0.57, p<0.0001). Le 
AUC per i miR selezionati sono risultate significativamente superiori a quella del 
CA125. 
I nostri risultati confermano che questi miR sono implicati nella patogenesi del 
cancro all'endometrio e potrebbero essere utilizzati come marcatori di diagnosi 
precoce. 
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I lavori condotti dal nostro gruppo di ricerca in quest’ambito, indicano che gli 
acidi nucleici circolanti sono una fonte potenzialmente promettente di 
biomarcatori tumore-specifici in pazienti affetti da diverse forme di cancro. 
Senza dubbio, il valore diagnostico di tali marcatori epigenetici, in pannelli 
multipli o in combinazione con biomarcatori tradizionali, potrebbe essere 
superiore a quello osservato per marcatori utilizzati singolarmente. 
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1. INTRODUCTION 
1.1 Epigenetic and cancer  
Cancer is a major public health problem in the United States and many other parts 
of the world. The overall estimate of 1,658,370 new cases is the equivalent of 
more than 4,500 new cancer diagnoses each day in 2015 (1). 
Cancer is not a single disease, but a diverse group of conditions that all share in 
common an increase in cell numbers within particular tissues.  
The development of colorectal cancer (CRC), for example, is a multistep process 
that involves an accumulation of mutations in tumor suppressor genes and 
oncogenes. It has provided a useful model for the understanding of the multistep 
process of carcinogenesis, characterized by the disruption of various cellular 
processes through the damage of their control mechanisms (2). 
These are mainly faulty DNA repair system, dysfunctional cell cycle checkpoints 
leading to excessive cell proliferation, the failure of apoptosis, loss of contact 
inhibition, and cellular migration into other tissues to form distant metastases. 
Hanahan et al. in 2000 (3) proposed that six hallmarks of cancer together 
constitute an organizing principle that provides a logical framework for 
understanding the remarkable diversity of neoplastic diseases. These six hallmarks 
were: sustaining proliferative signalling, evading growth suppressors, activating 
invasion and metastasis, enabling replicative immortality, angiogenesis and 
resisting cell death. 
Implicit in their discussion was the notion that as normal cells evolve 
progressively to a neoplastic state, they acquire a succession of these hallmark 
capabilities, and that the multistep process of human tumor pathogenesis could be 
rationalized by the need of incipient cancer cells to acquire the traits that enable 
them to become tumorigenic and ultimately malignant. 
It has long been accepted that genetic alterations can cause cancer, however, 
throughout the last decades the importance of epigenetic changes in initiation and 
progression of cancer has been widely acknowledged. The genetic and epigenetic 
processes seem to be interconnected in driving the development of tumours. 
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The cancer stem cell hypothesis was first proposed 150 years ago. Cell surface 
marker expression analysis indicates that cells of tumours can be sorted into a 
major and a minor population, where the latter constitutes less than 1% of the 
cells in the tumour (4). The cells of the minor population display several abilities 
which resemble those of stem cells, for example self-renewal and differentiation, 
both crucial properties in driving malignancy. Self-renewal drives tumorigenesis, 
whereas differentiation contributes to the heterogeneity phenotype of the tumours. 
Because stem cells have an unlimited ability to proliferate, it is likely that the 
tumorigenic cancer stem cells are the drivers of multistep tumorigenesis (5). 
However, accumulating evidence in the recent years indicate that tumor cell 
heterogeneity is in part due to significant contribution of ‘epigenetic’ alterations 
in cancer cells (6-8). Consequently, it is now becoming apparent that epigenetic 
plasticity together with genetic lesions drives tumor progression, and that cancer 
is the manifestation of both genetic and epigenetic modifications. 
Genetic information of an organism is encoded in the DNA sequence. 
“Epigenetics” refers to the regulation of gene expression through certain chemical 
changes such as DNA methylation or histone modifications or the function of 
noncoding RNAs, without involving mutational changes in DNA sequence (9). 
The term “epigenetics” was coined by Conrad Waddington in 1942 (10) and 
initially taken to describe the discipline in biology that studies “the interactions of 
genes with their environment that bring the phenotype into being” (11). 
In 2009, a more complete definition proposed that “an epigenetic trait is a stably 
heritable phenotype resulting from changes in a chromosome without alterations 
in the DNA sequence” (12). In fact, all cells of a complex multicellular organism 
contain the same genetic information but during development, each single cell 
differentiates into a specific phenotype without any changes in DNA sequence. 
This feature of epigenetics implies that the accuracy of epigenetic modifications is 
vital for maintaining the genome integrity and the cell phenotype. Aberrant 
epigenetic modifications are associated with different heritable (for example 
imprinting disorders and some cancers) and non-heritable diseases (for example 
most cancer types). Indeed, epigenetics contributes to the understanding of 
mechanisms underlying different diseases for which genetic mutations are not the 
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only cause. Among the possible epigenetic modifications, DNA methylation, 
histone modifications and microRNAs (miRs) expression are the most intensively 
studied by epigenetic researchers for unravelling their role in gene expression 
regulation and their involvement in diseases.  
Historically, the epigenetics was used to describe all biological phenomena that do 
not follow normal genetic rules. Nowadays, the field of epigenetics is considered 
as one of the most rapidly expanding fields of modern biology that has enormous 
influences on the understanding of biological phenomena and diseases, including 
cancer.  
Recent work suggests that the global epigenetic changes in cancer may involve 
the dysregulation of hundreds of genes during tumorigenesis (13). 
The mechanism by which a tumor cell accumulates such widespread epigenetic 
abnormalities during cancer development is still not fully understood. The 
selective advantage of these epimutations during tumor progression is possible, 
but it is unlikely that the multitude of epigenetic alterations that reside in a cancer 
epigenome occur in a random fashion and then accumulate inside the tumor due to 
clonal selection. A more plausible explanation would be that the accumulation of 
such global epigenomic abnormalities arises from initial alterations in the central 
epigenetic control machinery, which occur at a very early stage of neoplastic 
evolution. Such initiating events can predispose tumor cells to gain further 
epimutations during tumor progression in a fashion similar to accumulation of the 
genetic alterations that occurs following defects in DNA repair machinery in 
cancer. The “cancer stem cell” model suggests that the epigenetic changes, which 
occur in normal stem or progenitor cells, are the earliest events in cancer initiation  
(14).  
Since epigenetic mechanisms are central to maintenance of stem cell identity (15), 
it is reasonable to speculate that their disruption may give rise to a high-risk 
aberrant progenitor cell population that can undergo transformation with gain of 
subsequent genetic mutations. Such epigenetic disruptions can lead to an overall 
increase in number of progenitor cells along with an increase in their ability to 
maintain their stem cell state, forming a high-risk substrate population that can 
readily become neoplastic on gain of additional genetic mutations.  
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Moreover, genetic and epigenetic mechanisms are not separate events in cancer; 
they can intertwine and take advantage of each other during tumorigenesis. 
Alteration in epigenetic mechanisms can lead to genetic mutations, and genetic 
mutations in epigenetic regulators lead to an altered epigenome (16). 
 
1.2 DNA methylation  
DNA methylation is a widely used epigenetic control mechanism in cells (17) and 
it is associated with the silencing of repetitive and centromeric sequences and 
transposable elements throughout the genome, as well as in genomic imprinting 
and X-chromosome inactivation (dosage compensation in human females) (18).  
DNA methylation is involved in the control of genomic imprinting, which is an 
epigenetic form of gene regulation whereby a gene or genomic domain can be 
biochemically marked with information about its potential origin. Methylation of 
cytosine (C) in CpG repeat-rich elements is considered to be the one of the most 
important epigenetic traits in the regulation of transcriptional repression in 
mammals (19). 
In normal tissue the methylation of particular subgroups of CpG island promoters 
can be detected.  Impacts on gene transcription due to DNA methylation may 
occur in two different ways: 
1. The binding of transcriptional proteins to the gene may be physically impeded 
by DNA methylation (20) 
2. More importantly, methyl-CpG-binding domain proteins (MBDs) may bind to 
methylated DNA (21)  
Jin et al. proposed a direct and simple mechanism for transcriptional regulation by 
DNA methylation. They showed in their work that altered affinity/stability 
between Tfs (Trascription Factors) and DNA elements caused by DNA 
methylation (particularly by non-CpG methylation) can serve as a direct source 
for fine tuning of gene expression (22). 
DNA methylation is also influenced by histone modifications (23). 
After MDBs binding, they are recruited more proteins to the locus such as histone 
deacetylases and other chromatin remodelling proteins. The ATP-dependent 
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chromatin assembly factor (ACF), for example, is a dimeric motor that spaces 
nucleosomes to promote formation of silent chromatin (24). 
These proteins can also recruit histone modifying enzymes that alter nearby 
chromatin.  
Aberrant patterns of DNA methylation may cause “incorrect” gene expression of 
certain genes, and in cancer, aberrant methylation, as well as both 
hypomethylation and hypermethylation, have been observed.  
 
1.2.1 Molecular mechanism of methylation genes  
The existence of methyl-modified cytosine (5mC) in nature was first discovered 
in 1925 by Johnson and Coghill, as a structural unit of nucleic acids isolated from 
tubercle bacillus, as anticipated by Wheeler and Johnson, the first to synthesize 5-
methyl-cytosine in 1904. More than two decades after Johnson and Coghill’s 
discovery, Wyatt showed that 5mC occurred in the nucleic acids of higher animals 
and plants (25). Cytosine methylation in vertebrates occurs predominantly at CG 
dinucleotide sequences (26), termed CpG sites.  A family of proteins, known as 
the DNA methyltransferases (DNMTs), catalyzes the transfer of a methyl group 
from S-adenosylmethionine to a cytosine residue  (27). 
Four known DNMT proteins exist in mammals: Dnmt1 (28), Dnmt3A/B (29), and 
Dnmt3l (30).  
Work by Bessman et al. in 1958 characterizing the function of DNA polymerase 
showed that the enzyme cannot distinguish between the methylated and 
unmethylated cytosine nucleotide (31) prompting the possibility for the existence 
of a methyltransferase responsible for propagating 5mC through DNA replication.  
Dnmt1 was originally reported by Bestor et al. (32). Dnmt1 contains proliferating 
cell nuclear antigen (PCNA)-binding and replication foci targeting sequence 
(RFTS) domains, which are thought to contribute to maintenance methylation 
during replication. (33). 
Dnmt1 also shows a preference for hemi-methylated DNA in which one strand is 
methylated, although it has de novo DNA methyltransferase activity (34). This set 
of features is the reason why Dnmt1 is often referred to as the ‘maintenance 
methyltransferase’. 
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Dntm3a and Dnmt3b are responsible for the de novo methylation of unmethylated 
DNA (35) and have both overlapping and disparate DNA sequence affinities. 
Although somatic tissues show very little expression of Dnmt3a or Dnmt3b, 
Dnmt3a is ubiquitously expressed throughout the early embryo while Dnmt3b 
expression is specific to the forebrain and eyes. Dnmt3b isoforms can act as 
accessory proteins that interact with catalytically active enzymes to re-establish 
DNA methylation and could be one of many key factors for initiation of de novo 
DNA methylation during tumorigenesis (36), while Dnmt3a has been shown to 
methylate all CpGs regardless of genomic context (37). 
Dnmt3a and Dnmt3b seem also to play a role in methylation maintenance. Early 
knockout studies showed that embryonic stem cells lacking Dnmt3a and Dnmt3b 
enzymes lose nearly all 5mC over progressive cell divisions, indicating Dnmt1 is 
insufficient to fully maintain 5mC (38).  
Dnmt3 has no active methylase domain but seems to play a role in ensuring 
proper methylation of imprinted loci and transposable elements through the 
interaction with Dnmt3a and Dnmt3b.  
More recently, Dnmt3b together with Dnmt3a have been shown to be responsible 
for CpG and non-CpG methylation in oocytes (37). 
 
1.2.2 DNA methylation and cancer  
The function of tumor suppressors is often lost in cancers, enabling uncontrolled 
cell proliferation, division and growth. In addition to alterations in the genome 
tumor suppressor genes can also be silenced by promoter DNA hypermethylation 
(39).  
The majority of primary tumors show tissue-specific gains of methylation as 
compared to their normal counterparts (40). 
However, the mechanism of cancer-associated hypermethylation remains unclear. 
One possibility is that aberrant CpG island hypermethylation in cancer occurs 
through the interaction of increased DNMTs and oncogenic transcription factors 
(41-42). An analysis comparing normal and cancer cell lines also showed that the 
presence of stalled or active RNA polymerase in normal cells predicts resistance 
to aberrant hypermethylation in cancer cells (43). 
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Thirty years ago, the first epigenetic change observed in cancer was loss of pattern 
methylation. 
Hypermethylation in cancer has been suggested to occur in hight frequency at the 
CPG islands in the promotors regions (44).  
Another epigenetic process was global DNA hypomethylation. 
Hypomethylation is a process that reduces the methylation level of proto-
oncogenes in the cell. Some studies have found that, in a large variety of 
hypomethylated tumour samples, the changes in the cell are not only correlated 
with altered methylation patterns but also with increased tumour progression (45). 
Global DNA hypomethylation has been detected in various types of cancer such 
as breast (46), colorectal (47), ovarian (48). 
Hypomethylation has been located to the intergenic region associated with higher 
expression of repetitive DNA sequences (49). 
Consequently, particular DNA hypomethylations are linked to cancer initiation. 
Tumour cells also exhibit hypomethylation of CpG dinucleotides in various DNA 
regions that are responsible for increased gene expression, invasion and metastasis 
of cancer cells. 
 
1.2.3 Methods for DNA methylation analysis 
The appropriate approach for analysis of DNA methylation depends upon the 
goals of the study.  
The earliest studies on DNA methylation were aimed at determining the overall 
levels of 5-methylcytosines in the genome by hydrolysing DNA chemically and 
quantifying the hydrolysed products by high performance liquid chromatography 
(HPLC) (50). 
DNA hydrolysis can be carried out by incubation with formic acid at high 
temperature. 
However, Catania et al. (51) suggested the use of hydrofluoric acid for chemical 
hydrolysis of DNA to prevent deamination of cytosine and methylcytosine, which 
often occurs with formic acid. 
In any case, enzymatic hydrolysis of the DNA is reported to be a better alternative 
for quantifying the degree of DNA methylation (52). 
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Resulting deoxyribonucleosides are subsequently separated by HPLC, and the 
methylcytosine levels are quantified by comparing the relative absorbance of 
cytosine and methylcytosine at 254 nm in the sample with external standards of 
known bases. 
A major advance in DNA methylation analysis was the development of a method 
for sodium bisulfite modification of DNA to convert unmethylated cytosines to 
uracil, leaving methylated cytosines unchanged. 
This allows one to distinguish methylated from unmethylated DNA via PCR 
amplification and analysis of the PCR products. During PCR amplification, 
unmethylated cytosines amplify as thymine and methylated cytosines amplify as 
cytosine. 
Methylation-specific PCR (53), is one of the most effective choices for 
investigating the methylation profile of these regions. 
It is an application of bisulfite sequencing method. For a sequence in a gene 
containing CpGs, the allele on which those CpGs are methylated and another on 
which those CpGs are unmethylated should give different sequences after bisulfite 
modification. 
When a primers set that are complementary to the sequence with methylated 
CpGs, but are not complementary to the originally same sequence with 
unmethylated CpGs, is used for PCR, only the sequence (allele) with methylated 
CpGs should be amplified.  The same is true for the primer pair specific for 
sequence with unmethylated CpGs. 
An other assay is the LUMA (luminometric methylation assay) technique, 
published by Karimi and colleagues in 2006 (54). It utilizes a combination of two 
DNA restriction digest reactions performed in parallel and subsequent 
pyrosequencing reactions to fill-in the protruding ends of the digested DNA 
strands. One digestion reaction is performed with the CpG methylation-sensitive 
enzyme HpaII; while the parallel reaction uses the methylation-insensitive 
enzyme MspI, which will cut at all CCGG sites. 
The enzyme EcoRI is included in both reactions as an internal control. Both MspI 
and HpaII generate 5'-CG overhangs after DNA cleavage, whereas EcoRI 
produces 5'-AATT overhangs, which are then filled in with the subsequent 
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pyrosequencing-based extension assay. Essentially, the measured light signal 
calculated as the HpaII/MspI ratio is proportional to the amount of unmethylated 
DNA present in the sample. As the sequence of nucleotides that are added in 
pyrosequencing reaction is known, the specificity of the method is very high and 
the variability is low, which is essential for the detection of small changes in 
global methylation. LUMA requires only a relatively small amount of DNA (250–
500 ng), demonstrates little variability and has the benefit of an internal control to 
account for variability in the amount of DNA input. However, high quality DNA 
is essential to ensure that complete enzymatic digestion occurs, and the 
polymerase extension assay requires a pyrosequencing machine and reagents. 
WGBS (BS-seq; MethylC-seq) theoretically covers all the C information (55). In 
this method, genomic DNA is purified and sheared into fragments. The 
fragmented DNAs are end-repaired; adenine bases are added to the 3 end (A-
tailing) of the DNA fragments, and methylated adapters are ligated to the DNA 
fragments (56). The DNA fragments are size-selected before sodium bisulfite 
treatment and PCR amplification, and the resulting library is sequenced. It should 
be noted that a high number of PCR cycles and inappropriate selection of a uracil-
insensitive DNA polymerase may result in an over-representation in the 
methylated DNA data (57). Starting with sufficient genomic DNA may avoid a 
loss of information from regions of interest and over-amplification. 
The major advantage of WGBS is its ability to assess the methylation state of 
nearly every CpG site, including low- CpG-density regions, such as intergenic 
‘gene deserts’, partially methylated domains and distal regulatory elements. It can 
also determine absolute DNA methylation level and reveal methylation sequence 
context. 
 
1.3 Histone modifications 
Chromatin is the higher order of organization of genomic information. 
Nucleosome constitutes its basic unit, which is composed by a histone octamic 
protein core. 
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The structure of the nucleosome core is relatively invariant from yeast to 
metazoans (58) and includes a 147 bp segment of DNA and two copies each of 
four core histone proteins. 
Chromatin proteins function as building blocks to package eukaryotic DNA into 
higher order chromatin fibers. Each nucleosome encompasses a tetramer of 2 
histone 2A (H2A) and 2 histone 2B (H2B) molecules, flanked by H3 and H4 
dimers. The histone proteins coordinate the changes between tightly packed DNA 
(heterochromatin) that is inaccessible to transcription and exposed DNA 
(euchromatin) that is available for binding to transcription and regulation of 
transcription factors (59). 
Histone proteins contain a globular C-terminal domain and an unstructured N-
terminal tail. 
The N-terminal tails can undergo a variety of post-translational covalent 
modifications including acetylation, methylation, phosphorylation, ubiquitination 
and ADP ribosylation on specific residues, the most studied of which are 
acetylation and methylation of specific lysine residues on histones H3 and H4 
(60). 
About 30 short chains of amino acids protrude from the histones. These ‘histone 
tails` are subjected to various post‐translational modifications, which form a 
‘histone code`. By defining the accessibility of the transcription machinery to 
genes and gating the accessibility of the genome to other machineries, such as 
repair and DNA replication, the ‘histone code` regulates chromatin function and 
thus determines gene expression patterns. Within the histone tails, lysine (K) and 
arginine (R) residues are the major sites of modifications. Reversible acetylation 
and methylation of the basic side chains of these amino acids are common (61). 
Histone acetylation was the first histone modification described and 
hyperacetylated histones were early associated with open chromatin formation 
and transcriptional activation (62).  
Histone tails have a large number of lysine residues, which act as target for 
histone acetyltransferase (HATs) and histone deacetylases (HDACs). Both hyper 
and hypo histone acetylation of individual lysine, are associated with 
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trascriptional state. Histone acetylation can effected transcription by causing a 
confirmation change of nucleosome core, allowing a greater accessibility of DNA. 
The attachment of acetyl groups to lysine residues goes along with two functional 
consequences. First, the positive charge of physiologically protonated ε-amino 
groups is abolished, resulting in altered electrostatic as well as steric properties of 
the affected protein region. Second, acetylation serves as a mark for distinct 
“reader” domains, which comprise specialized tertiary structures (e.g., 
bromodomains) in proteins that undergo a selective interaction with acetylated 
lysines (63). 
Upon acetylation, local affinity of the modified histone protein to negatively 
charged DNA is decreased, resulting in a less condensed chromatin structure and 
in exposure of promoter sites. As a consequence of the increased accessibility, the 
DNA globally becomes more prone to access of the transcriptional machinery 
(64). 
On the other hand, acetylation of histones can attract proteins to elongated 
chromatin that has been marked by acetyl groups histone modifications serving as 
a signalling platform to recruit or occlude effector proteins. (65). These factors 
specifically recognize modifications via unique domains. They possess enzymatic 
activities such as remodelling ATPases and following their binding they can 
further modify chromatin.  
 
1.3.1 Histone acetylation and diseases 
Acetylated histones represent a type of epigenetic marker within chromatin. 
Modifications of histones cannot only cause secondary structural changes at their 
specific points but can also cause structural changes in distant locations which can 
also affect function. 
Aberrant acetylation levels have been connected with a diversity of disease 
phenotypes including cancer, neurological disorders, and cardiovascular and 
metabolic malignancies (66-68). 
Dysfunction of HDAC enzymes has been linked with a variety of human diseases, 
because the reversal of acetylation by HDACs correlates with transcriptional 
repression. HDACs can regulate diverse cellular functions, including cell cycle 
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progression, survival, proliferation (69-70) and also changes in histone acetylation 
have been reported to associate with inflammation (71). 
For example Nitric Oxide (NO) plays an important role in a variety of physiologic 
and pathophysiologic processes in multiple tissues, as inflammation process. NO 
is a dual regulator of inflammation, contributing to vasodilation and cell activation 
as well as to processes involved in the resolution of inflammation. 
The interaction of HDAC isoforms and NF-kB proteins to alter acetylation 
provides the potential to fine-tune the expression of iNOS and other downstream 
target genes contributing to inflammatory responses (72). 
Because these are ubiquitously expressed and involved in cell proliferation and 
survival, aberrations in their gene expression have been implicated in a wide 
range of cancers. HDAC1–HDAC3 genes are over-expressed in ovarian cancer 
tissues and probably have a significant role in ovarian carcinogenesis (73); these 
HDAC isoforms are also highly expressed in Hodgkin’s Lymphoma (HL). 
However, decreased HDAC1 expression is accompanied by worse outcome in HL 
(74). Over-expression of HDAC1 has also been reported in prostate and gastric 
cancers (75), while contrastingly, under-expression was reported in colorectal 
cancer (76). 
Because of the broad acceptance of substrates, histone acetyltransferases and 
deacetylases are hence often referred to as lysine acetyltransferases (KATs) and 
lysine deacetylases (KDACs), respectively (77). 
Lysine acetylation of histone and non-histone proteins are generally linked to 
activation of transcriptional activity and therefore affects pivotal physiological 
processes within an organism. As a consequence of misregulated acetylase 
activity, the manifestation and progression of certain malignancy phenotypes 
correlates with pathological aberrations of the acetylation equilibrium. This could 
be either due to altered activity of the responsible enzymes or because of changes 
in their expression levels. The role of distinct KAT subtypes in diseases like 
cancer, neurodegenerative disorders, viral and parasitic infections, inflammation, 
and metabolic and cardiovascular malignancies have been extensively 
investigated (78-79). 
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CREB-binding protein (CBP) and p300 are highly conserved and functionally 
related transcription coactivators and histone/protein acetyltransferases and 
involved in multiple cellular processes. 
In human cancer, spontaneously occurring mutations in the P300 gene, that acts as 
a crucial element in the eukaryotic gene regulation network was shown to be 
regulated by phosphorylation, which greatly reduces its HAT activity (80-81). 
This reinforce the idea that indicate P300/CBP (PCAF) activity can be under 
abnormal control in human disease, particularly in cancer, which may inactivate a 
p300/CBP tumor-suppressor-like activity (82). 
p300 and CBP seem to have a dual role in oncogenesis; they can be either friends 
or foes. On the one hand, genetic studies show that they can act as tumor 
suppressors, as CBP and p300-null chimeric mice develop hematological 
malignancies. (83-84).  
In addition to histone proteins, HDACs have many non-histone protein substrates, 
including p53 and STAT, which are important transcription factors regulating the 
expression of a large number of genes (85). 
P53 acts as a tumor suppressor protein by inhibiting cell cycle progression and S-
phase entry. Several reports have been shown that acetylation of the C-terminal 
regulatory domain is involved in regulating activity of p53 (86). 
Acetylation of this site is observed after DNA damage in vivo, induced p53 and 
caused cell cycle arrest or apoptosis; therefore, over expression of PCAF can 
cause growth arrest (87). 
 
1.3.2 Methods for histone acetylation analysis 
Antibody-based techniques such as western blotting have been extensively 
adopted to characterize histones. However, antibody-based approaches are limited 
for the following reasons: I) they can only confirm the presence of a modification 
and cannot identify unknown histone post-translational modifications  (PTMs); II) 
they are biased due to the presence of co-existing marks, which can influence 
binding affinity; III) they cannot identify combinatorial marks, as only very few 
antibodies are available for such purpose and IV) they cross-react between highly 
similar histone variants or similar PTMs (e.g., di- and trimethylation of lysine 
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residues). Egelhofer et al. described that more than 25% of commercial antibodies 
fail specificity tests by dot blot or western blot, and among specific antibodies 
more than 20% fail in chromatin immunoprecipitation experiments (88). 
Mass spectrometry (MS) is currently the most suitable analytical tool to study 
novel and/or combinatorial PTMs, and it has been extensively implemented for 
histone proteins (89).  
This is mostly due to high sensitivity and mass accuracy of MS, and the 
possibility to perform large-scale analyses. 
A different method to analyze the chromatin is the chromatin 
immunoprecipitation (ChIP). This involves crosslinking of the protein–DNA 
complex within an intact cell using crosslinking agents, such as formaldehyde. 
The DNA is then sheared to smaller pieces (‐500 bp) by sonication or nuclease 
digestion. The sheared protein-bound DNA is then immunoprecipitated using a 
highly specific Ab against the protein. An aliquot of the sheared DNA before 
immunoprecipitation is used as a reference sample. The protein–DNA complexes 
from reference and ChIP samples are then reverse crosslinked. The DNA is 
purified and enrichment of ChIP-ed DNA over the reference sample can be 
analyzed using a number of techniques, such as quantitative PCR, sequencing or 
microarray (90).  Although ChIP has been widely used in other model systems, 
there are only a few labs that have successfully used ChIP in Caenorhabditis 
elegans (91). 
 
1.4 MicroRNAs 
MicroRNAs (miRNAs) are endogenous, non-coding RNAs that are ~22 
nucleotides in length. MiRNAs control gene expression by binding to target 
mRNAs leading to their degradation or repression of translation (92). 
MiRNA biogenesis begins in the nucleus where they are transcribed by RNA 
polymerase II (RNA Pol II) as long transcripts known as primary miRNA (pri-
miRNA) (93). Like mRNAs, pri-miRNAs are poly-adenylated at the 3′ end and 
carry a 7-methyl-guanosine cap at the 5′ end (94).  
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Pri-miRNA is cleaved by the RNase III enzyme Drosha into a shorter (<100 bp) 
transcript known as the precursor miRNA (pre-miRNA) composed of a stem-loop 
structure which encodes the mature miRNA sequence in the stem  (95). 
The export receptor Exportin-5 (Exp5) binds to pre-miRNA and exports it from 
the nucleus into the cytoplasm (96). Once in the cytoplasm, the terminal base 
pairs and loop of the pre-miRNA are cleaved off by another RNase III enzyme, 
Dicer. This cleavage leaves a small double stranded RNA referred to as the 
miRNA:miRNA* duplex (97). 
One strand of this duplex forms the mature miRNA and is incorporated into the 
RNA-induced silencing complex (RISC). The RISC is a ribonucleoprotein that 
contains the mature miRNA and an Argonaute (Argo) protein which is believed to 
be responsible for translational repression (98). 
The resultant complex between mature miRNA and RISC is denominated miRSC. 
In mammals, selection of the guide strand is dictated by thermodynamic stability, 
the less stable strand at the 5´ end has more probability of being incorporated into 
the RISC; the remaining strand (miRNA*-passenger strand) is excluded and 
generally degraded (99). 
However, miRNA sequencing data, demonstrate that a large number of miRNA* 
are not degraded and are expressed in similar concentrations to their 
corresponding guide strand (100). 
Once the mature miRNA is incorporated into the RISC this complex inhibits the 
translation of target mRNA through 1) mRNA cleavage 2) mRNA destabilization or 
3) translational repression (101). 
Identification of miRNA targets has been difficult because only the seed sequence 
(about 6–8 bases) of the approximately 22 nucleotides aligns perfectly with the 
target mRNA’s 3 untranslated region (102). 
Bioinformatics approaches can identified putative targets for particular miRNAs 
through analysis of the miRNA seed sequences, (103) however, these miRNAs 
need to be assayed in vitro or in vivo to determine if they truly affect the proposed 
mRNA. Once a sequence has been determined to be a unique miRNA, the 
miRBase registry assigns a name according to existing guidelines (104). 
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In the database, a sequence of 3 or 4 letters designates the species (e.g., “hsa” for 
Homo sapiens); however, this prefix is usually dropped in the literature. The core 
of the miRNA name is the designation “miR” (denoting a mature sequence) 
followed by a sequentially assigned unique identifying number. Lettered suffixes 
are added to miRs that differ by only 1 or 2 bases (e.g., miR-10b), and numbered 
suffixes are assigned to miRs that have the same sequence but are derived from 
different primary transcripts. A suffix of 5p or 3p is given when mature miRNAs 
are derived from the 5  arm or the 3 arm, respectively, of the precursor miRNA. 
 
1.4.1 MicroRNAs and cancer 
Epigenetic profiling of miRNAs has revealed new insights into the altered 
epigenetic regulation of these molecules in diseases, including cancer. 
Therefore, it is not surprising that studies have found miRNAs to be involved in many 
cellular processes including development, cell proliferation, apoptosis, fat 
metabolism, and cell differentiation (105). 
Cancer in particular has been a major focus of microRNA research over the past 
decade, and many studies have demonstrated the importance of microRNAs in 
cancer biology through controlling expression of their target mRNAs to facilitate 
tumor growth, invasion, angiogenesis, and immune evasion (106). 
For almost three decades, carcinogenesis has been primarily attributed to 
abnormalities in oncogenes and tumor-suppressing genes. It is now recognized 
that miRNA also have a primary role in cancer onset and progression. Oncomir is 
the term used to describe an miRNA involved in cancer.  
With such widespread regulatory functions in gene expression and key roles in 
cancer associated cellular processes, the roles of miRNAs in cancer are now being 
extensively explored. 
Abnormal miRNA expression in malignant cells compared with normal cells are 
often attributed to alterations in genomic miRNA copy numbers and gene 
locations (amplification, deletion or translocation). 
The earliest discovery of miRNA gene location change is the loss of miR-15a/16-
1 cluster gene at chromosome 13q14, which is frequently observed in B-cell 
chronic lymphocytic leukemia patients (107). 
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This microRNA deletion was shown to act at least in part through allowing higher 
expression of the miR-15/16 anti-apoptotic target B-cell lymphoma 2 (BCL2). 
Since then it has been documented that microRNAs have roles in all of the cancer 
hall-marks defined by Hanahan and Weinberg (108), and are implicated in the 
clinical management of cancers at every stage.  
Although many specific examples have been reported, microRNA functions fall 
into two broad major functional categories: (i) homeostatic regulation of gene 
expression, through ‘fine-tuning’ of translation according to cellular requirements; 
and (ii) robustness in cellular responses, which is important in cell fate decisions 
in which groups of microRNAs can dictate the cellular differentiation state, acting 
as ‘locks’ to maintain cell identity, often via complex reciprocal negative-
feedback loops (109). 
MiRNAs discovery led to a worldwide research effort to establish their roles in 
cancer. MiRNAs regulate molecular pathways in cancer by targeting various 
oncogenes and tumour suppressors, and have a role in cancer and stem cell 
biology, angiogenesis, the epithelial–mesenchymal transition, metastasis, and 
drug resistance. For example the let-7 miRNA family has a role in cancer by 
negatively regulating  RAS (110). 
O’Donnell et al. (111) discovered that c-Myc, frequently upregulated in many 
malignancies to regulate cell proliferation and apoptosis, activates the 
transcription of oncogenic miR-17–92 cluster through binding to E-box elements 
in miR-17–92 promoter. Consistent with its oncogenic role, c-Myc also represses 
transcriptional activity of tumor suppressive miRNAs such as mir-15a, miR-26, 
miR-29, mir-30 and let-7 families. 
In recent years, studies on miRNAs, especially on a large scale using microarrays, 
have provided a more comprehensive picture on the role of abnormal miRNA 
expression in neoplasia (112). 
Recently, a number of onco-miRNAs such as miR-9, miR-155, and miR-21 have 
been shown to be implicated in cancer therapeutic response, inducing 
chemoresistance by modulating the expression of resistance-associated genes 
(113-114). 
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Wang et al. has identified in plasma, microRNA profiles (miR-21, miR-27a, and 
miR-218) for primary resistance to EGFR-TKIs in advanced lung cancer with 
EGFR activating mutation (115). 
Further studies are demanded in order to use microRNA profiles as diagnostic 
markers and conduct microRNA-based therapies in clinical practice. 
 
1.4.2 Methods for analysis of miRNAs 
The first step in qPCR of miRNAs is the accurate and complete conversion of 
RNA into complementary DNA (cDNA) by reverse transcription. However, this 
step is challenging as: 
i. the template has a limited length (22 nt); 
ii. there is no common sequence feature to use for the enrichment and 
amplification of miRNAs; 
iii. the mature miRNA sequence is present in pre- and the pri-miRNAs. 
A range of techniques have been developed to overcome the challenges of 
miRNA profiling, as qPCR assay, miRNA array, RNA-seq. 
 
Quantitative PCR miRNA assay 
One of the most popular techniques for validating and accurately quantifying 
miRNAs is quantitative real time PCR (qPCR). As well as being sensitive and 
quantitative, qPCR is also relatively inexpensive and flexible making it the 
preferred choice for validating novel miRNAs and for use in relatively small 
experiments. 
This technique begins with the conversion of miRNA to cDNA. With the length 
of a miRNA being comparable to that of a typical DNA primer, cDNA synthesis 
from miRNAs presents its own challenges. The solution to this is to make the 
molecule longer, either by incorporating a poly(A) tail or stem-loop structure.  
In poly(A) RT-qPCR, total RNAs, including miRNAs, are initially polyadenylated 
and reverse transcribed using poly(T) adapters into cDNAs, which are called 
poly(A) RT, and qPCR is subsequently performed using an miRNA-specific 
forward primer and a partial sequence in the poly(T) adapter as the reverse primer. 
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Once miRNA has been converted to cDNA it can be assayed using the same 
approach as a conventional qPCR experiment. Amplification is initiated with an 
miRNA-specific primer and a stem-loop/poly(A) primer. Either SYBR®Green or 
a TaqMan® probe is used to detect the amplified product.  
 
MiRNA array 
Arrays are typically chosen for larger studies covering multiple miRNA targets. 
While they are the least quantitative of the three miRNA assay methods, 
conventional DNA oligonucleotide arrays are a relatively inexpensive way to 
measure hundreds of targets at once. 
Thousands of probes can be easily spotted on slides, or built up by 
photolithography, potentially enabling the parallel tracking of all known miRNAs. 
Arrays are probed by hybridizing fluorescently labelled DNA or RNA samples. 
The brightness of individual spots can be used to infer relative changes in 
expression between samples. 
 
RNA-seq 
This method of miRNA quantification uses the high-throughput capability of 
next-generation sequencing (NGS) platforms. While it cannot quantify miRNA 
levels with the molar resolution of qPCR, deep sequencing of miRNA does have 
the advantage of being able to sample all miRNAs present in a sample, whether 
the researcher knows the sequence or not, making it an ideal discovery tool. 
Furthermore, as sequences are read directly, RNA-seq can distinguish closely 
related miRNAs and isoforms  
Currently, quantitative PCR (qPCR) is the favoured method for determining 
miRNA expression, due to its accuracy, simplicity, reproducibility and lower cost 
than other hybridization or sequencing-based technologies. 
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1.5 Circulating nucleic acids 
Capturing and analysis of circulating biomarkers is an alternative method to gain 
insight into the molecular make-up of a cancer in a given patient. 
Many cancers may remain asymptomatic until relatively late stages. 
In managing the disease, effort ought to be focused on early detection, accurate 
prediction of disease progression, and frequent monitoring. The current gold 
standard of cancer diagnosis is based on histology evaluation of tissue biopsies. 
Tumor cells release DNA or RNA into the blood, and this offers the opportunity 
to determine the genetic landscapes of solid cancer from the circulation, an 
approach commonly called 'liquid biopsy”. 
Alterations in epigenetic profiling may provide important insights into the 
aetiology and natural history of cancer. Since several epigenetic changes occur 
prior to histopathological changes (116), they can serve as biomarkers for cancer 
diagnosis and risk assessment. 
The emergence of advanced technologies to detect genome-wide epigenetic 
changes holds promise to advance our capacity to develop such biomarkers for 
detecting cancers at early stage. 
In solid tumours, circulating biomarker scan be released into bloodstream through 
various events including necrosis, apoptosis, and other physiological mechanisms 
in thestromal microenvironment. Therefore, ‘liquid biopsies’ can capture spatial 
and temporal heterogeneity during tumour formation and evolution. Epigenetic 
aberrations offer dynamic and reversible targets for cancer therapy. Increasingly, 
alterations via over expression, mutation, or rearrangement are found for genes 
that control the epigenome (117). 
The history of circulating nucleic acids goes back to a finding in 1947 by Mandel 
and Metais of RNA and DNA in the plasma of healthy and sick individuals (118). 
The presence of DNA and RNA in plasma of cancer patients has been recognised 
since the 1970s (119). 
But it was not until the late 1980 that this circulating DNA was shown to exhibit 
tumour related alterations (120). 
During the 1990, a large number of tumour associated genetic and epigenetic 
changes were detected in the plasma/serum of cancer patients: Ras and p53 
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mutations, microsatellite alterations, aberrant promoter hypermethylation of 
several genes, rearranged immunoglobulin heavy chain DNA, mitochondrial DNA 
mutations, and tumour related viral DNA (121-122). 
In general, concentrations of cfDNAs are higher in individuals with cancer than in 
healthy controls, and levels are further increased in metastasis. Both tumor-
derived and normal germline cfNAs are released into the blood, and the 
proportion of tumor-derived cfNA is broadly related to the extent of the disease 
(123). 
In 2007 Lawrie et al., reported the presence of miRNAs in the blood of lymphoma 
patients (124); the following year, it was demonstrated that miRNAs could be 
useful as non-invasive biomarkers of cancer (125). 
The presence of DNA and RNA in exosomes, vesicles that are actively released 
by multiple cell types (including neoplastic cells), is also well documented. (126-
128). 
Indeed intercommunication between cancer cells and with their surrounding and 
distant environments is key to the survival, progression and metastasis of the 
tumour. Exosomes play a role in this communication process (129). 
MicroRNA expression is frequently dysregulated in tumour cells and can be 
reflected by distinct exosomal miRNA (ex-miRNA) profiles isolated from the 
bodily fluids of cancer patients. 
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2. AIMS  
The knowledge of the fundamental epigenetic mechanisms governing gene 
expression and cellular phenotype is sufficiently advanced that novel insights into 
the epigenetic control of cancer disease are now emerging. Researchers are in the 
process of shedding light on the roles played by DNA methylation, 
histone/chromatin modifications and non-coding RNAs in specific pathologies. 
The development of new early detection techniques is essential to improve the 
outcome of patients with cancer. Blood-based biomarkers offer promising means 
of non-invasive detection however few molecules have been found that have a 
sensitivity and specificity high enough to be used in standard clinical practice. For 
example the finding that miRs are stably expressed in human plasma and serum 
and that they are differentially expressed in patients with cancer suggests the 
utility of these molecules as biomarkers not only for early detection, but also as 
means of monitoring disease progression and recurrence. However, further 
research into the factors that influence circulating miRNA expression and 
quantification is required before the full potential of these molecules as cancer 
biomarkers can be achieved.  
The aims of this thesis were: 
1) to analyse the status of the two best characterized CRC genetic and epigenetic 
(KRAS mutations and SEPT9 methylation) alterations in a cohort of CRC 
patients, and to compare the degree to which the two patterns move from 
tissue to plasma in order to improve our understanding of biology modulating 
the concordance between tissues and plasma methylation and mutation 
profiles; 
2) to investigate serum expression levels of miR-199a and miR-125b in ovarian 
cancer patients in comparison to healthy controls, and to evaluate the 
correlation between miRs expression and traditional biomarkers serum 
concentrations (i.e., CA125 and HE4); 
3) to investigate the differential expression of four serum miRs (miR-222, miR-
223, miR-186 and miR-204) in EC patients in comparison to healthy subjects. 
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3. PAPERS 
3.1 Comparison of genetic and epigenetic alterations of primary 
tumors and matched plasma samples in patients with colorectal 
cancer  
(PLoS One 2015;10:e0126417, Reproduced with permission from Plos One) 
Introduction 
The finding that tumor specific genetic and epigenetic alterations can be detected 
in circulating DNA extracted from plasma of cancer patients has shown promise 
for improving early diagnosis, prognostication and disease monitoring. The 
overarching goal of utilizing cell free DNA as a biomarker entails medical 
practice optimization, personalized medicine development, and quality of life 
improvement due to the minimal invasiveness of blood testing. However, there is 
still a challenge to authenticate the actual clinical validity of various cfDNA 
alterations as putative cancer biomarkers in clinical practice (1). Currently, the 
main issue is represented by the fact that circulating DNA fragments carrying 
tumor specific alterations represent a variable and generally small fraction of the 
total circulating DNA, thus generating a high variability in concordance rate 
between alteration patterns detectable in tissue of primary tumors and 
corresponding plasma.  
The factors influencing the quantitative as well as qualitative changes of cfDNA 
with respect to tissues of cancer patients are multiple and not yet fully explored so 
far. However, efforts during the last decade have led to important advances.  
By evaluating the methylation pattern of the PCDH10 gene in tissue and plasma 
of patients with CRC we have recently demonstrated that the methylation rate 
detected in plasma increased with increasing methylation rate in tumour tissues 
only in early-stage cancers, whereas this correlation was apparently lost in 
advanced cancers. Moreover, we showed that the degree of cfDNA methylation 
was associated with some characteristics of cfDNA, such as its concentration and 
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integrity, and that these correlations varied in strength and direction in parallel 
with tumour stage (2).  
In the last two years two independent research groups showed that the possibility 
to detect tumor specific cfDNA in plasma of CRC patients largely depends on the 
sensitivity of the PCR-based method for short mutated sequences (3-5), thus 
emphasizing the importance of minimizing the assay length when analyzing 
highly fragmented cfDNA, such as in the setting of cancer patients. 
A further issue which complicates the use of cfDNA as liquid biopsy for cancer is 
the intratumoral heterogeneity and clonal evolution during progression, both 
factors resulting in differences in the proportion and pattern of aberrations 
detectable in the primary tumor and in the circulating DNA (6,7). 
According to this evidence, different technical and biological aspects should be 
considered when analysing the variable concordance between tissue and plasma 
alterations in cancer patients, not least the nature of the underlying alterations.  
Both epigenetic and genetic alterations are well known aberrations involved in 
colorectal carcinogenesis. Given their enormous potential as biomarkers in CRC 
diagnosis, staging, prognosis and response to treatment, they have been 
extensively investigated in the last decade. However, a critical comparison of their 
status in tissue and cfDNA is lacking. Therefore, this study was aimed to analyze 
the status of the two best characterized genetic and epigenetic alterations of CRC 
(i.e., KRAS mutation and SEPT9 promoter methylation) in a cohort of CRC 
patients, in order to improve our understanding of the biological aspects 
modulating the concordance between tissues and plasma methylation and 
mutation profiles. Then, we also compared the degree at which the genetic and the 
epigenetic patterns move from tissue to plasma. 
 
Material and Methods 
Patients and Samples 
The study cohort included 85 consecutive patients undergoing surgery for CRC at 
the University Hospital of Verona (Italy) between January 2010 and December 
2010. Blood specimens were collected before intervention. Tumor samples were 
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obtained during the surgical procedure, immediately frozen in liquid nitrogen and 
stored at -80°C. Histological diagnosis and tumor stage were determined 
according to the 2000 World Health Organization (WHO) classification system 
for tumors of the digestive system and the American Joint Committee on Cancer 
(AJCC) staging system, respectively (8). Only patients with primary colorectal 
adenocarcinomas untreated with neoadjuvant radio-chemotherapy were included 
in the study. All subjects provided informed consent prior to collection of 
samples. The study was approved by the local ethical committee (Department of 
Life and Reproductive Sciences, University of Verona) and performed in accord 
with the Helsinki Declaration of 1975. Clinical information was obtained from 
medical records.  
 
DNA isolation from plasma and tissue samples  
Blood samples were collected in 7 mL EDTA tubes and processed within 1 h of 
collection. After double centrifugation (800g for 10 min centrifugation, followed 
by separation and a second 1600g for 10 min centrifugation) plasma was 
separated, stored in aliquots and frozen at –80°C until processing. DNA was 
extracted from plasma and fresh frozen tissue sections by the QIAamp DNA 
Blood midi kit and the Gentra Purgene Kit (Qiagen, Hilden, Germany) 
respectively.  
 
cfDNA concentration and Integrity index 
cfDNA fragmentation was assessed by calculating the DNA Integrity index as 
previously described (2). In brief, it was determined by calculating the ratio of 
larger (247 bp) versus shorter (115 bp) targets of the consensus sequence of 
human ALU repeats.  
The ALU-qPCR result obtained with ALU115 primers was also used to quantify 
total DNA.  
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Methylation specific PCR (MSP) 
Purified genomic DNA extracted from tissues and plasma was subjected to 
bisulfite treatment and DNA purification using the Epitect Bisulfite kit (Qiagen, 
Hilden, Germany) according to manufacturer’s instructions. A detailed protocol 
has been previously reported elsewhere (2). 
Bisulfite-modified DNA was used as template for Real-Time PCR using a Sybr 
green-based quantitative MSP. Primers for MSP were designed to specifically 
amplify either a bisulfite-sensitive, unmethylated strand or a bisulfite-resistant, 
methylated strand on the SEPT9 gene promoter region. The web-based software 
MethPrimer (http://itsa.ucsf.edu/urolab/MethPrimer) was used to select a specific 
CpG island, which was recently found to display the highest susceptibility to 
methylation changes in the adenoma-carcinoma sequence (9). 
The sequences of the primer sets were as follows:  
M-Fo: TTATTATGTCGGATTTCGCGGTTAAC 
M-Rev: AAAATCCTCTCCAACACGTCCG  
U- Fo: TAGTTATTATGTTGGATTTTGTGGTTAATG  
U- Re:  CAAAATCCTCTCCAACACATCCAC  
(M: methylated, U: unmethylated). 
The CpGenome Universal Methylated DNA (Chemicon, Millipore Billerica, MA, 
USA) was used as 100% methylated (positive) control and DNA extracted from 
peripheral blood mononuclear cells of normal individuals was used as 
unmethylated (negative) control. 
The PCR reaction mixture was prepared in a final volume of 20 µl, consisting of 
final concentration: 0.375 µM of forward and reverse primers, 250 µM of each 
dNTP (GE Healthcare, Little Chalfont, UK), 1× HotStart Buffer (Qiagen), 2.5 
mM MgCl2, 1.5 units HotStart polymerase (Qiagen), 2 µM SYTO 9 (Invitrogen, 
Life Technologies, Carlsbad, CA), and 1×ROX reference dye (Invitrogen), 3 µl of 
bisulfite-modified DNA. 
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The PCR amplification was performed with precycling heat activation of DNA 
polymerase at 95 °C for 10 min, followed by 40 cycles of denaturation at 95 °C 
for 30 sec, annealing at 64 °C for 30 sec and extension at 72 °C for 30 sec. An 
ABI Prism 7500 Sequence Detection System (Applied Biosystems – Foster City, 
CA, USA) was used. 
The PCR product was run on an 2% agarose gel to confirm product size and the 
specificity of PCR, and then visualised under UV light. A band of 110 bp was 
considered as diagnostic of methylation status, whereas a band of 114 bp was 
considered as diagnostic of unmethylation status. 
 
KRAS mutation analysis 
DNA extracted from tissue and plasma samples was subjected to an allele 
refractory mutation system qPCR (ARMS-qPCR) for detection of six of the most 
common mutations in codons 12 and 13 of the KRAS gene (G12A, G12D, G12V, 
G12S, G12C, and G13A). DNA was amplified in a 25 µl reaction mixture 
containing 0.25 µM of  each amplification primer, 200 µM of each dNTP (GE 
Healthcare, Little Chalfont, UK), 1× HotStart Buffer (Qiagen, Hilden, Germany), 
2 mM MgCl2, 2 units HotStart polymerase (Qiagen, Hilden, Germany), 2 µM 
SYTO 9 (Invitrogen, Life Technologies, Carlsbad, CA), 1×ROX reference dye 
(Invitrogen) and 25 ng DNA. The primer sequences have been previously 
described elsewhere (10), with the exception of the common reverse primer which 
has been re-designed in order to shorten the amplicons of both codon 12 (90 bp) 
and codon 13 (85 bp) (originally of 149 and 144 bp in length). The resulting 
sequence was as follows: TGTTGGATCATATTCGTCCACA. 
The PCR amplification was performed with precycling heat activation of DNA 
polymerase at 95 °C for 10 min, followed by 40 cycles of denaturation at 95 °C 
for 30 sec, annealing at 64 °C for 30 sec and extension at 72 °C for 30 sec, in a 
ABI Prism 7500 Sequence Detection System (Applied Biosystems – Foster City, 
CA, USA). The PCR product of mutated samples was run on a 2% agarose gel to 
confirm the presence of the specific bands.  
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Quantitative analysis and analytical performance 
Threshold cycles (Ct) were used to calculate the methylation rate and the mutation 
load in each sample according to the follow formula: %= 100 / [1 + 2{Ctmet/mut – 
Ctunmet/WT}] (2,11). Ctmet and Ctunmet denote threshold cycles specific for the 
methylated and unmethylated state, whereas Mut and WT refer to mutated and 
wild-type alleles, respectively. The proportions (%) of methylation rate or 
mutation load detected in plasma compared to those detected in tissues were 
expressed as plasma/tissue ratio (p/t ratio).  
The median of at least two replicate measurements was calculated for each sample 
and used for statistical analysis. Predefined quality criteria were set such that 
measurements with Ct values greater than 38 cycles were excluded.  
Since it has been observed that the sensitivity of cfDNA assays can be increased 
by shortening the size of amplicons (5,6), primers for both analyses were designed 
to allow the amplification of products smaller than 120 bp. The intra-assay 
imprecision for the methylation test was 9%. The lower limit of detection of 
methylated DNA for the MSP assays (assessed using serial dilutions of the 
Universal Methylated DNA) was 1.5%.   
The intra-assay imprecision for the KRAS analyses ranged between 2% and 8%, 
depending on the type of mutation. Cell line DNA admixtures containing the 
mutation of interest in a normal DNA background was used to evaluate the limit 
of detection and amplified in the same instrument runs to act as positive controls. 
The analytical sensitivity of ARMS-qPCR was below 2%, as previously reported 
(12).  
 
Statistical analysis 
Normality distribution was checked with the Shapiro-Wilk test and continuous 
variables were reported as median (range) or mean±SD, when appropriate. 
Statistical analyses and plotting of data were performed with GraphPad Prism 
(GraphPad Software Inc., San Diego, CA). The diagnostic performance of cfDNA 
analysis was compared with the tumor-tissue analysis (the current gold standard) 
for its sensitivity and specificity in distinguishing between 
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mutated/hypermethylated and nonmutated/non methylated individuals. The 
predictive positive values and negative predictive values were also calculated with 
Fisher’s exact test. The rate of concordance between tissue and plasma profiles 
was determined with agreement test (and values presented as weighted kappa ± 
standard error). Differences between continuous variables were analyzed by using 
the Mann-Whitney U test. Correlations were tested with the Spearman correlation. 
Values of p<0.05 were considered statistically significant. 
 
Results 
Fifty six of 85 patients initially evaluated for their potential inclusion in the study 
were men, the remaining women, (mean age 69±14 years). The tumor stage 
distribution was as follow: 15 patients were at stage I (17.6%), 35 at stage II 
(41%), 24 at stage III (28.2%) and the remaining 11 at stage IV (12.9%). Twenty 
nine out of 85 tumor tissue samples (34%) were positive for one of the six KRAS 
mutations tested. Of these, 22 tumor tissues showed matched mutations in plasma 
samples. There were nine discordant results among the 85 samples examined. 
Five results showed a WT genotype for KRAS-tested mutations by cfDNA 
analysis, whereas tumor-tissue analysis showed a KRAS G13D mutation (n=2), a 
KRAS G12D mutation (n=2) or a KRAS G12V mutation (n=1). Two patients (both 
at stage II) showed a KRAS G12S and a G12A mutation by plasma analysis, but 
were determined as WT by tumor-tissue analysis. Finally, two patients (both with 
advanced metastatic CRC) showed unmatched mutations between tissue and 
plasma. Overall, cfDNA analysis showed 89% concordance for KRAS detection 
with tumor-tissue analysis.  
The SEPT9 promoter methylation was present in 82.3% (70/85) of primary tumor 
tissue samples. The analysis exhibited 86% of concordance with cfDNA analysis. 
Discordant results only concerned patients with aberrant methylation of SEPT9 in 
tissue samples and unmethylated plasma samples (n=12). The distribution of 
positive and negative samples in tissue and plasma is shown in table 1 along with 
the analytical performance of cfDNA analyses. 
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Tumors-tissue analysis 
NPV 
93% 
  
  
  
NPV 
56% 
  
PPV 
85% 
  
  
  
PPV 
94% 
  
SP 
93% 
  
  
  
SP 
100% 
  
SE 
85% 
  
  
  
SE 
83% 
  
Total 
27 
58 
85 
  
Total 
58 
27 
WT 
5 
53 
  
 
Unmethylated 
0 
15 
Mutant 
22 
5 
27 
  
Methylated 
58 
12 
cfDNA analysis 
KRAS 
Mutant 
WT 
Total 
Agreement 76/85 (89.4%) 
k=0.753±0.077, p<0.0001 
SEPT9 
Methylated 
Unmethylated 
 
Table 1: Concordance between tumor-tissue analysis and cfDNA analysis (n = 85) 
cfDNA: cell-free DNA; WT: wild type; SE: sensitivity; SP: specificity; PPV: positive predictive value; NPV: 
negative predictive value. 
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After exclusion of the two patients with different KRAS genotype in tissue and 
plasma, the 27 patients (81.5% male) presenting with both genetic and epigenetic 
alterations in tissue specimens (31.8%, 27/85) were considered for further 
quantitative analyses. In these patients the rate of concordance between tissue and 
plasma was 93% (25/27) for the epigenetic alteration and 81% (22/27) for the 
KRAS mutation analysis (i.e., two cfDNA samples were negative for the 
methylation of SEPT9 and five were negative for the presence of KRAS 
mutations). Among the different KRAS mutations tested, the G12V substitution 
was the most represented (n=11), followed by G12D (n=7) and G13D (n=7). 
Finally, one sample had the G12A mutation and one the G12S. Overall, 74% and 
26% of mutation sites were located in codons 12 and 13, respectively. 
The median SEPT9 methylation rates in tumour tissues and plasma samples were 
64.5% (12.2–99.9%) and 14.5% (0–45.5%), respectively. The median KRAS 
mutation load was 33.6% (1.8-86.3%) in tissues and 2.9% (0-17.3%) in plasma 
samples. Quantitative data for both genetic and epigenetic alterations according to 
different clinical pathological characteristics are summarized in Table 2. In both 
tumour tissues and plasma samples, no significant associations were found for  
gender, primary tumor site and differentiation status. In terms of pathological 
stage classification, the median methylation rate of SEPT9 was significantly 
higher in advanced-stage cancer tissues than in the early stage tissues. A 
statistically significant correlation was found in the cohort between tissue and 
plasma SEPT9 methylation rate (r=0.407, p=0.035), whereas no association was 
found between tissue and plasma KRAS mutation load (r=0.092, p=0.651)
 5
5
 
 
             
Table 2: Associations between SEPT9 methylation rate and KRAS mutation load in tissue and plasma samples 
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Additional analyses were performed on p/t ratio of KRAS mutation load and 
SEPT9 methylation rate to identify any potential difference between genetic and 
epigenetic degree of transition from tissue to plasma. The p/t ratio of SEPT9 
methylation rate was significantly higher than the p/t ratio of KRAS mutation load 
(24.2% vs 7.9%, p=0.023), both parameters showing a wide spectrum of values 
(range 0-72.9% for SEPT9 p/t ratio and 0-62.6% for KRAS p/t ratio). This result 
was almost entirely attributable to the large discrepancy between genetic and 
epigenetic p/t ratios detectable in early stage cancers (p=0.0108), since the 
difference in advanced stage cancers was no longer significant (p=0.68) (Figure 
1).  
 
Figure 1: Differences between plasma/tissue methylation rate and mutation load 
in early and advanced cancer stages. 
 
The concentration of cfDNA in early stages CRC patients (median 30.6 ng/mL, 
4.6-66.8) was lower than that in advanced stage patients (80.2 ng/mL, 31.0-195.0; 
p=0.0001), and was also found to be more fragmented (integrity index: 0.36, 
0.0.7-0.85 vs 0.63, 0.33-0.95; p=0.0163). No significant associations were found 
between cfDNA parameters and genetic or epigenetic alterations, except for a 
weak correlation between cfDNA integrity index and KRAS mutation load in 
advanced cancers (r=0.572, p=0.040). 
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Discussion 
Although the use of cfDNA as potential surrogate of cancer genome has been 
originally suggested more than 30 years ago (13), and the role of liquid biopsy has 
been evaluated for its predictive and prognostic value in a number of settings with 
promising results, cfDNA-based cancer tests have not been developed for clinical 
use so far.  
The high degree of fragmentation coupled with the low blood concentration make 
cfDNA a challenging analyte under a technical perspective. Moreover, the current 
lack of knowledge about the kinetic of release of tumor-related cfDNA into the 
bloodstream and the genetic composition changes during progression contribute to 
render cfDNA a “hard to read” analyte even under a biological perspective.  
The results of our study, other than confirming that liquid biopsy predicts 
alterations of tumor tissues, are consistent with the hypothesis that some 
differences may exist among the rate with which genetic and epigenetic alterations 
move from tissue to plasma.  
In order to make results free from any potential technical interference and make 
genetic and epigenetic data reliable and directly comparable, we adopted a 
number of methodological expedients adapted from recent publications. Firstly, 
plasma was used for analysis since this biological matrix represents a better 
source of cfDNA than serum (1,6). Then, we used relative short amplicons for 
both determinations, and this was due to the fact that amplicons length could 
influence the sensitivity of mutation and methylation detection (5,14,15). We have 
also assured a high level of sensitivity for epigenetic assay by targeting a specific 
CpG island, which has been recently found to display the highest susceptibility to 
methylation changes in the adenoma-carcinoma sequence (9). Finally, according 
to the American Society for Clinical Oncology and National Comprehensive 
Cancer Network (NCCN), a high level of detection rate has been obtained for the 
KRAS mutation analysis by targeting hotspots in codon 12 and 13, which are 
known to account for approximately 95% of all mutations (16). 
In the present study, a methylation specific qPCR and an ARMS-qPCR based 
methods were used for SEPT9 methylation analysis and KRAS mutation analysis, 
respectively. Owing to technological advances, new methods, including digital 
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PCR (17), Inteplex qPCR (14) BEAMing technology (18), MethyLight 
quantitative or MethyLight digital PCR (19) and new deep sequences approaches 
(20) are now available and allow absolute quantification of mutant or methylated 
alleles at very low frequencies and with lowest coefficient of variations than those 
reported here. However, the assays that we used in this study are those most 
widely available in clinical laboratories and are also characterized by optimal 
sensitivity, being able to detect at least 2% mutant in a normal background (21). 
Most importantly, the analytical performances of the genetic and epigenetic 
assays were very similar in terms of both sensitivity and precision, which has 
allowed to directly compare data of different alterations.  
The first part of the study, performed on the entire cohort of 85 CRC patients, 
substantially confirmed previous evidence that analysis of KRAS and SEPT9 in 
plasma represents a reliable alternative to the tissue. The status of KRAS is 
generally used as a predictive marker for response to established epidermal 
growth factor receptor (EGFR) inhibitors due to the fact that mutant KRAS is 
associated with resistance to anti-EGFR monoclonal antibody immunotherapy 
with agents such as centuximab or panitumumab (22,23). Conversely, aberrant 
methylation in the promoter region of the SEPT9 gene has been convincingly 
proposed as sensitive and specific biomarker for early non-invasive diagnosis of 
CRC (24). 
By following the suggestions recently proposed by Wasserkort and co-authors (9) 
thus targeting a specific CpG island on the promoter of the SEPT9 gene, we found 
a very high number of hypermetylated tissues samples (82%) and even higher 
than that previously reported in the literature (usually ranging between 78 and 
81%) (25). The results obtained in matched plasma samples revealed a very high 
global concordance (86%) and specificity (100%) compared with tumor-tissue 
analysis. In the same sample, a KRAS mutation was detected in the 34% of 
patients, in accord with data obtained in other cohorts of unselected CRC patients 
(10,26). The corresponding analysis of plasma samples also revealed a high 
degree of concordance (89.4%) and specificity (93%) compared with tissue. Most 
of the studies comparing the results from a cfDNA assay with tumor-tissue 
analysis reported a much lower diagnostic performance, with values of specificity 
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constantly lower than 80% (27-29). As an exception only two recent studies 
reported values of specificity comprised between 95.3% (30) and 98% (14). 
In the second part of the study, we have also analysed the rate of concordance 
between tissue and plasma mutation load and methylation rate, and then compared 
results obtained with the two assays. In the subgroup of 27 patients harbouring 
tissue genetic and epigenetic alterations, the KRAS mutation load varied from 1.8 
to 86.3% (almost 48-fold), thus showing a higher inter-individual heterogeneity 
than the SEPT9 methylation rate, which varied from 12.2% to 99.9% (8-fold). In 
the transition from tissue to plasma, five samples became wild type for the 
mutation status and two were no longer hypermethylated. The degree of 
methylation moving from tissue to plasma was almost 3 times higher than the rate 
of mutation load as resulting from comparison of the two p/t ratios (24.2% vs 
7.9% for p/t ratio of SEPT9 methylation rate and KRAS mutation load, 
respectively). In agreement with recent reports, this finding might be explained by 
the intratumoral heterogeneity of the primary tumor, which preferentially impairs 
genetic rather than epigenetic analysis (7,31). However, since the discrepancy 
found between the two p/t rations is exclusively attributable to results obtained in 
early stage cancers, whereas clonal evolution usually occurs when metastasis 
develop, the tumor clonality would only partially explain our data (32).  
For the KRAS analysis, comparable values of mutation load were obtained 
between early and advanced cancers in both tissue (26.9% vs 34.7%) and plasma 
samples (1.9% vs 4%), so that the p/t analysis did not revealed significant 
difference according to the tumor stages (8.6% vs  7.3%). Conversely, a statistical 
significant difference was found for the SEPT9 methylation analysis between p/t 
ratio in early and advanced cancers (33.8% vs 19.0%, p=0.0108). This difference 
was entirely attributable to a discrepancy in the methylation rate detected in 
tissues (57.2% vs 80.8%, p=0.0009), since no differences were found in plasma 
samples (15.8% vs 12.9% for early vs advanced stages). Thus, the transition of 
DNA harbouring the epigenetic alteration into the circulation in early stage 
cancers is seemingly more consistent than the transition of DNA harbouring a 
KRAS mutation. According with the most recent literature, this data could be 
interpreted as the result of differences in tissue types involvement previously 
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observed for CRC genetic and epigenetic signatures (33). In particular, while the 
aberrant methylation SEPT9 originates in epithelial cells and is then rapidly 
transferred to stromal cells (9), the KRAS mutations harboured by epithelial 
compartment are not shared by stromal cells (34). Accordingly, the molecular 
cross-talk between tumor epithelium and stroma occurring for the SEPT9 
epigenetic alteration might facilitate the transition of aberrant DNA from primary 
tumour to the circulation.  
In conclusion, the results of the present study confirm that cfDNA analysis 
represents a suitable strategy for comprehensive analysis of tumor genetic and 
epigenetic profiles, even using routinely standard methods. Most importantly, we 
provided first evidence that the rate at which tumor derived cfDNA can be 
detected into the circulation not only depends on the sensitivity of methods used 
and the complexity of release kinetics, but also on the nature of the single 
alteration. In an era of increasing use of genome-scale comprehensive gene 
expression studies of solid tumors to elucidate the complexity of tumor tissues and 
heterogeneity of cell phenotypes, our study emphasize the need to better 
characterize cancer specific genetic and epigenetic signatures according to 
different tumour compartments in order to improve the significance and clinical 
value of cfDNA assessment.  
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3.2 MiR-199a and miR-125b expression levels in serum of 
patients affected by epithelial ovarian cancer 
(Biochim Clin 2016;40:328-33, Reproduced with permission from Biochimica 
Clinica) 
 
Introduction 
The Epithelial Ovarian Cancer (EOC) is the leading cause of gynaecological 
cancer-related mortality worldwide, since it is commonly detected at an advanced 
and scarcely curable stage (1). Age-standardised incidence rates range from more 
than 9,1 per 100 000 women in Central and Eastern Europe (2). The crude 
incidence rate in Europe changes from 12,4 per 100.000 in the age group of 40-44 
years to 35,9 per 100.000 in the age group of 60-64 years. Since EOC is generally 
asymptomatic in the early stages, about 75% of patients are diagnosed at an 
advanced stage (3). 
The Cancer Antigen 125 (CA125) is the “gold standard” for monitoring patients 
affected by EOC, although being characterized by low sensitivity and specificity 
(4). Accordingly, elevated serum CA125 concentrations can be found not only in 
a broad range of benign gynaecologic diseases, but also in malignancies of 
different origin, including non-ovarian gynaecologic cancers, other epithelial 
tumors and non-epithelial malignancies (5).  
Another serum biomarker, cleared by the Food and Drug Administration (FDA) 
for monitoring patients with EOC, is human epididymis protein 4 (HE4). Serum 
measurement of HE4 shows advantages over CA125 in terms of specificity, as it 
is less frequently increased in patients with non malignant ovary diseases. In 
2008, The FDA has approved the combined use of HE4 and CA125 for estimating 
the risk for ovarian cancer in women with a pelvic mass. Updated guidelines do 
not recommend  the use of these biomarkers is not recommended for determining 
the status of an undiagnosed pelvic mass (6). 
Although recent meta-analyses have reported that HE4 exhibits higher rule-in 
capability for EOC vs CA125 more studies focusing on early tumour stages are 
required (7-9). 
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Carcinogenesis is characterized by the accumulation of both genetic and 
epigenetic alterations which can be used as disease biomarkers to provide 
important information for early detection of malignant diseases usually 
asymptomatic at early stages (10-11). Notably, the number of genes involved in 
development and progression of tumours which are epigenetically silenced 
probably overcomes the number of genes inactivated by mutation (12). Recent 
reports showed that methylated DNA and microRNAs (miRs) expression could be 
readily detected in a wide variety of tissues, as well as in various body fluids, 
indicating that these epigenetic biomarkers could represent the next generation 
biomarkers for cancer detection (13-14). MiRs, a class of small non-coding RNAs 
involved in regulating a variety of biologic processes (15-16), have been reported 
to be stably detectable in plasma and serum (17-18), and to exhibit resistance to 
endogenous ribonuclease activity (19). 
By targeting multiple transcripts, a single miR can regulate many fundamental 
cellular processes such as cell proliferation, apoptosis, differentiation and 
migration. On the other hand, any gene can be regulated by multiple miRs (20). 
Alterations in miR expression are not simply an effect of tumorigenesis and may 
have a causative role in cancer development. They are involved in the initiation, 
progression and metastasis of human tumors. Iorio et al. (21) first evaluated 
genome-wide miR expression profiles of ovarian cancer tissues and normal ovary 
tissues, concluding that miRs expression was differentially regulated in the two 
groups. More specifically, miR-200a, miR-141, miR-200c and miR-200b were 
found to be over-expressed in ovarian cancer, while miR-199a, miR-140, miR-
145, and miR-125b were down-regulated. Both miR-199a and miR-125b are 
involved in many biological processes including inhibition of tumor angiogenesis, 
a fundamental process for cancer development and growth. These miRs mainly 
act by targeting the 3′ untranslated region of VEGF (22), by increasing NF-κB 
activity (23) and by negatively regulating tumor suppresor p53 (24).  
Therefore, the aim of our study was to investigate the serum expression levels of 
miR-199a and miR-125b in ovarian cancer patients in comparison to healthy 
controls, and to evaluate the correlation between miRs expression and 
concentrations of CA125 and HE4. 
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Materials and methods 
Patients and samples 
The study population consisted in 32 consecutive patients (54±14 years) 
diagnosed with EOC, and enrolled between December 2007 and February 2013 at 
the Obstetrics and Gynecology Clinics of the University Hospital of Verona 
(Italy). Blood was drawn in vacuum tubes containing no additives (Becton-
Dickinson, Oxford, UK) prior to any therapeutic procedure (i.e., surgery, 
chemotherapy or radiotherapy). After centrifugation at 1,500g for 10 min at room 
temperature, serum was separated, stored in aliquots and kept frozen at -80°C 
until measurement. The histopathology results were confirmed by surgical 
resection of the tumors, and the tumor stage was defined according to the 
International Federation of Gynecology and Obstetrics (FIGO) system criteria 
(25). The demographics and clinical features of the patients are listed in Table 1. 
The control population consisted of 31 healthy female controls (55±17 years), 
matched by age and ethnicity, and without previous or recent history of cancer or 
other diseases. The study was carried out in accordance with the ethical standards 
of the revised Declaration of Helsinki.  
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Variables Ovarian cancer (n=32) 
Age, years (±DS) 54.1 (±14.3) 
     ≥ 55 anni, n (%) 15 (46.9) 
     < 55 anni, n (%) 17 (53.1) 
FIGO stage, n (%)  
     I 4 (12.5) 
     II 2 (6.25) 
     III 26 (81.25) 
Histological grade, n (%)  
     1 4 (12.5) 
     2 7 (21.9) 
     3 21 (65.6) 
Histology, n (%)  
     Endometrioid 4 (12.5) 
     Clear cells 4 (12.5) 
     Undifferentiated 2 (6.2) 
     Mixed epithelial tumor 3 (9.4) 
     Serous 18 (56.2) 
     Transitional 1 (3.1) 
Table 1. Demographics and clinical features of ovarian cancer patients. 
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Laboratory methods 
Serum levels of CA125 were measured using a chemiluminescent enzyme 
immunoassay on the Liaison (DiaSorin, Saluggia, Italy). Intra and inter-assay 
coefficient of variation (CV) for this method are comprised between 1.4–2.2 and 
4.6–5.8%, respectively. Serum levels of HE4 were determined using ELISA kit 
developed by Fujirebio Diagnostic, Inc. (Malvern, PA) and were performed 
according to the manufacturer’s specifications. Total CV quoted by the 
manufacturer is <10%.  
The isolation of miRNA from serum samples was performed with the 
miRNeasyTM RNA isolation kit (Qiagen, Valencia, CA, USA) according to the 
manufacturer’s instructions. Briefly, 200 ml of serum sample was  added with 1 
ml of QIAzol Lysis Reagent (Qiagen) and mixed by gentle vortexing. Aqueous 
and organic phase separation was achieved by addition of chloroform. The 
aqueous phase was applied to an RNeasy spin column. The microRNA was eluted 
from the column with 14 µl of nuclease-free water. Quantity of RNA was assessed 
using small-RNA chip on Bioanalyzer 2100 (Agilent, Santa Clara, USA). RNA 
aliquots were stored at -80°C. For miRNA qPCR, reverse transcription was 
performed using TaqMan® MicroRNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA, USA) in a total volume of 10 µL containing 3.33 µL 
RNA, 1 µL 10 × reverse transcription buffer, 0.67 µL Mutiscribe Reverse 
Transcriptase, 0.13 µL RNase Inhibitor. The reaction mixture was incubated for 
30 min at 16 °C, 30 min at 42 °C, 5 min at 85 °C for 5 min, and then held at 4°C. 
The complementary DNA (cDNA) served as the template for Real-Time PCR. 
The reactions were performed in triplicate on a 7500 Real-Time PCR System 
(Applied Biosystems, CA, USA) using TaqMan MicroRNA assay (Applied 
Biosystems, Foster City, CA, USA). Briefly, qRT-PCR was carried out in a total 
of 20 µl volume containing 1.33 µl cDNA, 1 × Universal PCR Master Mix and 1 
µL gene-specific primers and probe. PCR parameters were as follows: 95°C for 10 
min, followed by 40 cycles of 95°C for 15 s, and 60°C for 1 min. The comparative 
cycle threshold (Ct) method was applied to quantify the expression levels of 
miRNAs. The relative amount of miR-199a and miR-125b to small nuclear miR-
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16 was calculated using the equation 2-∆Ct, where ∆Ct= (Ct miR-199a/miR-125b 
- Ct miR-16) (26). 
 
Statistical analysis 
Data were tested for normality using the D'Agostino and Pearson omnibus 
normality test. Non-normally and normally distributed variables were reported as 
median (range) or mean ± standard deviation (SD), respectively. The 
concentration of the different biomarkers were compared between cases and 
controls using Kruskall-Wallis and Mann–Whitney tests according to their value 
distribution. The correlation between variables was assessed with Spearman’s 
correlation coefficient (rs). For each miRNA and serum biomarkers, the 
diagnostic performance in terms of discriminatory capability was calculated by 
means of receiver operator characteristic (ROC) curves. The statistical analysis 
was performed using GraphPad Prism 5.0 (GraphPad Software, San Diego 
California USA), and the level of statistical significance was set at p<0.05..3  
 
Results 
The serum concentrations of both CA125 and HE4 were found to be significantly 
higher in EOC patients than in controls (Table 2). The median CA125 and HE4 
levels were not statistically different between advanced EOC stage (III) and early 
EOC stage (I-II) (Table 2).  
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1
 
 
 
P value 
 
0.69 
0.24 
Grade 3  
(n=21) 
174.9  
(3.3-3158.0) 
136.8  
(34.1-2300.0) 
Grade 1-2 
(n=11) 
96.0  
(6.5-2176.0) 
81.6  
(43.6-861.0) 
P value 
 
0.22 
0.14 
Stage III 
(n=26) 
201.8  
(3.3-3158.0) 
128.1  
(34.1-2300.0) 
Stage I-II 
(n=6) 
38.1  
(6.8-2176.0) 
76.9  
(43.6-208.0) 
P value 
 
<0.0001 
<0.0001 
Controls 
(n=31) 
12.0  
(5.0-32.0) 
37.5  
(25.0-121.2) 
Patients 
(n=32) 
174.6  
(3.3-3158.0) 
123.6 
(34.1-2300.0) 
  
CA125, U/mL 
HE4, pmol/L 
Table 2. CA125 ed HE4 concentrations in EOC patients and healthy controls. 
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In EOC patients, a statistically significant correlation was found between CA125 
and HE4 levels (r=0.46, p=0.009).  
The serum concentrations of miR-199a and miR-125b were found to be 
significantly higher in EOC patients compared to healthy controls (p=0.007 and 
p=0.002, respectively) (Figure 1). The serum levels of miR-199a and miR-125b 
were not significantly higher in patients with advanced cancer (FIGO stages III) in 
comparison to early stages (I and II) (p=0.72 and p=0.12). Moreover, miR-199a 
and miR-125b serum levels were found to be not significantly different in patients 
with grade 3 EOC compared to those with grade 1 and 2 (p=0.23 and p=0.35). A 
significant correlation was found between miR-199a and miR-125b serum levels 
(r=0.38, p=0.03). The serum concentration of miR-199a was not significantly 
correlated with CA125 or HE4 values, whereas miR-125b expression levels 
correlated significantly with CA125 (r=0.33, p=0.007) but not with HE4. The 
ROC curve analysis evaluating the capability to discriminate EOC from healthy 
conditions, revealed that the single measurement of HE4 exhibited a significantly 
higher area under the curve (AUC) compared to CA125, miR-199a and miR-125b 
(Figure 2).  
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Figure 1. MiR-199a and miR-125b expression levels in EOC patients and healthy 
controls. 
Figure 2. HE4, CA125, miR199a and miR-125b ROC curves performed on EOC 
patients and healthy controls. 
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Discussion 
Survival of women affected by EOC is higher when the diagnosis is made at an 
early stage, but it dramatically drops when the cancer has spread to the pelvis and 
peritoneum. Therefore, a better diagnostic approach is still needed to improve the 
clinical outcome (27). 
Several studies have demonstrated the limitations of using CA125 for detecting 
EOC. In fact CA125 may increase in patients with other malignant or 
gynaecological benign diseases (i.e. endometriosis), resulting in a poor diagnostic 
specificity and in a high rate of false-positive results (28). Furthermore a low 
sensitivity is generally well reported in all stages of ovarian cancer and 
particularly in early-stages (29). For these reasons CA125 is not useful to rule-out 
or rule-in patients for EOC. 
Between additional putative tumour biomarkers, HE4 seems the most promising 
(30-32). In our study, the AUCs for HE4 and CA125 were 0.90 and 0.85 
respectively, which agrees with previous evidence published by Ghasemi et al 
(33). Anyway  a considerable expression of HE4 in normal tissues and the lack of 
increase in borderline tumors are the main limitations to HE4 specificity (34-35). 
Accordingly to previous observations (36), we have also found that no significant 
difference exist in the concentration of HE4 among different EOC FIGO stages. 
However, this result could be due to the low sample size.  Accordingly, the major 
limit of our study is the small number of subjects investigated and in particular the 
low number of patients in early stages. 
Recently, miRs were identified as cancer biomarkers in cell-free serum, which can 
be used for distinguishing diseased individuals from healthy controls (37). They 
are readily detected in blood and they can be measured non-invasively, thus 
opening new avenues about the clinical usefulness of epigenetic biomarkers for 
early cancer detection (38-39). 
The results of our study suggest that miR-199a and miR-125b were up-regulated 
in serum of EOC patients compared to controls. In previous studies based on 
ovarian cancer tissues/cell lines, both these miRs resulted instead found to be 
down-regulated (21; 40). In another study earlier published by Chen et al., the 
expression of miR-199a was found to be significantly higher in Type II (high-
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grade, serous EOC) cancer compared with Type I EOC (41). Type I tumors 
comprise low-grade serous, low-grade endometrioid, clear cell and mucinous 
carcinomas. They are generally indolent, present in stage I (tumor confined to the 
ovary), and are characterized by specific mutations, including KRAS, BRAF, 
which target specific cell signaling pathways. These tumors rarely harbor p53 
mutations and are relatively stable genetically. Nevertheless, the significant 
difference between data obtained in these and previous studies can be reliably 
attributed to the different study populations enrolled, wherein 65,6% of our 
patients were diagnosed in the most advanced stage and 56,2% of the EOC were 
of serous origin. Notably, Chen et al. (41) previously described that hsa-miR-199a 
has a functional role in carcinogenesis, by regulating IKKβ expression, and this 
evidence is seemingly in support of our finding that this miRNA may be somehow 
involved in the pathogenesis of this type of cancer. 
As currently reported in the scientific literature, miR-125b may be up-regulated in 
some tumors and down-regulated in others (42). As regards its biological activity 
and function, this miRNA interplays with many target genes related to tumor 
growth, invasion and metastatic, progression survival and chemotherapy 
recurrence, but its specific metabolic pathway remains largely unclear (42). It has 
been recently shown that protein p53, a well-known anti-tumor molecule, is a 
putative miR-125b target (43). Le et al. (44), thus demonstrating that miR-125b 
may regulate cancer growth by inhibiting p53 expression through direct binding 
with p53 mRNA 3'UTR. 
Taken together, our results show that HE4 retains better diagnostic performance in 
EOC patients than the conventional cancer biomarker CA125, and also better than 
two promising miRNAs such as miR-199a and miR-125b. Currently, the 
identification of cancer-specific miRNA profiles in the circulation is an emerging 
field of particular interest.  Accordingly, the evidence that the serum level of these 
two miRNAs is considerably increased in patients with EOC underpins that their 
assessment may retain some biological interest in basic research and for 
increasing our understanding of the still intriguing EOC carcinogenesis. However, 
a number of studies remain to be performed to elucidate the biological 
significance of these miRNAs in ovarian cancer.  
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3.3 Aberrant miRNAs expression in patients with endometrial 
cancer 
(Int J Gynecol Cancer 2017 doi: 10.1097/IGC.000000000000091, Reproduced 
with permission from Int J Gynecol Cancer) 
 
Introduction 
Endometrial carcinoma (EC) is the most frequent gynaecological cancer in 
developed countries and second only to cervical cancer globally (1,2). Several 
randomized trials have confirmed that the initial stage of disease is the most 
important prognostic factor in EC (3). In particular, 5-years survival rate 
approximates 80% when the diagnosis is made at an early stage, but it 
dramatically decreases to nearly 15-17% when the cancer is diagnosed at stage IV. 
Despite several efforts that have focused on the identification of reliable 
biological markers, no specific serum tumor markers display satisfactory 
performance for either diagnosing or monitoring EC. The Human Epididymis 
Protein 4 (HE4), an innovative biomarker originally proposed for investigating 
other gynecologic malignancies (i.e., ovarian cancer) (4,5), was found to be 
sufficiently specific but poorly sensitive in patients with EC (6). Although the 
diagnostic performance of HE4 appears better than that of Cancer Antigen 125 
(CA125) in diagnosing EC at an early stage (7), its real value and efficacy for 
management of EC has not been clearly demonstrated in clinical practice. 
Therefore, discovery and validation of novel molecules, or panels of biomarkers, 
that can help identify endometrial tumors in their earliest stages with high 
sensitivity and specificity should be regarded as a major breakthroughs for 
improving the outcome of patients with this type of malignancy.  
Epigenetics, conventionally defined as heritable change in gene expression that is 
not attributable to alteration of the DNA sequence, represents a new avenue in 
cancer research. Reliable evidence is accumulating that epigenetic mechanisms 
may play a key role in cancer progression and as well as in the onset of 
chemotherapy resistance (8). Since blood can easily be collected through a 
minimally invasive procedure, and also provides the ideal substrate for miRNAs 
 82 
 
analysis, the assessment of non-coding RNAs (ncRNAs) has been proposed as a 
valuable perspective for early diagnosis of a kaleidoscope of different cancers (9). 
Aberrant tissue miRNAs expression has been described in EC (10-14) and, more 
recently, circulating extracellular miRNAs have been also been identified (15-17). 
Notably, a genome-wide study aimed to assess serum miRNA expression profile 
in EC identified four putative serum miRNAs (i.e., miR-222, miR-223, miR-186 
and miR-204), which may be potentially useful for diagnostics of EC (18). 
Therefore, this study was aimed to investigate the differential expression of four 
serum miRNAs, as well as the concentration of two widely used serum 
biomarkers (i.e., CA125 and HE4), in EC patients and in a healthy control 
population. 
 
Materials and methods  
Population 
The study population consisted in 46 consecutive women diagnosed with EC, who 
were scheduled to undergo radical surgical treatment between October 2007 and 
February 2010. The patients were recruited at the Obstetrics and Gynecology 
Clinics of the University Hospital of Verona (Italy). All patients underwent 
radiological imaging by pelvic ultrasonography (US), computed axial tomography 
(CAT) scanning, and/or magnetic resonance imaging (MRI) within 6 weeks prior 
to surgery, to identify the presence of endometrial mass. Blood samples were 
collected prior to any therapeutic procedure (i.e., surgery, chemotherapy or 
radiotherapy). The histopathology results were confirmed by surgical resection of 
tumors, and the cancer stage was defined according to the International Federation 
of Gynecology and Obstetrics (FIGO) system criteria (19). The control population 
consisted in 28 healthy female controls, matched by age and ethnicity, and 
without previous or recent history of cancer or other diseases. All healthy controls 
underwent gynaecologic examinations and transvaginal sonographies in the 
previous two years. The study was carried out in accordance with the ethical 
standards of the revised Declaration of Helsinki. 
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Laboratory methods 
Blood samples were collected in vacuum tubes containing no additives (Becton-
Dickinson, Oxford, UK) after overnight fast. All samples were collected from EC 
patients the morning before surgery. After centrifugation at 1500 x g for 10 min at 
room temperature, serum was separated, stored in aliquots and kept frozen at -80° 
C until measurement. 
Serum levels of CA125 were assayed with the chemiluminescent enzyme 
immunoassay CanAg CA125, on Triturus EIA analyzer (Grifols, USA). The intra- 
and inter-assay imprecision of this method is comprised between 2.9-4.4% and 
3.1-4.0%, respectively. The analytical sensitivity and the upper reference limit of 
the CanAg CA125 EIA assay are <1.5 U/mL and 35 U/mL, respectively. The 
serum levels of HE4 were measured using an EIA kit developed by Fujirebio 
Diagnostic, Inc. (Malvern, PA) on Triturus EIA (Grifols, USA). The HE4 EIA is a 
solid-phase, non-competitive sandwich immunoassay based on two mouse 
monoclonal antibodies directed against two epitopes of the C-WFDC domain of 
HE4. The total imprecision, the limit of detection and the functional sensitivity of 
this assay are <10%, <2.5 pmol/L and <5 pmol/L, respectively. Since no 
conclusive diagnostic threshold has been reported for HE4 so far, the value 
corresponding to the 95° percentile value of a healthy population (74.2 pmol/L) is 
conventionally used as diagnostic cut-off. 
Total serum RNA was extracted using mirVana PARIS Kit (Ambion, Life 
Technologies). The TaqMan MicroRNA Assay (Applied Biosystems, Foster City, 
CA) was used for quantitative real-time reverse transcriptase polymerase chain 
reaction (qRT-PCR) to verify differential miR expression on an ABI 7500 Real-
Time PCR (Applied Biosystems). Briefly, 250 ng of total RNA were transcribed 
under the following condition: 16° C for 30 min, 42° C for 30 min, 85° C for 5 
min. The PCR reaction conditions were as follows: 95 °C for 10 min, 40 cycle of 
95 °C for 15 sec and 60 °C for 1 min. All assays were performed in triplicate. The 
relative expression level of each miR was normalized to that of miR-16 (Applied 
Biosystems), and was finally calculated utilizing the 2-∆Ct method (20). 
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Statistical Analysis 
The values of the different biomarkers were described as median (and range). The 
concentration of the different biomarkers were compared between cases and 
controls using Kruskall-Wallis and Mann–Whitney tests. The correlation between 
variables was assessed with Spearman’s correlation coefficient (rs). The 
diagnostic performance was calculated by means of receiver operator 
characteristic (ROC) curves. The statistical analysis was performed using 
GraphPad Prism 5.0 (GraphPad Software, San Diego California USA), and the 
level of statistical significance was set at p<0.05. 
Results 
The demographics and clinical features of study population are described in Table 
I. The serum concentrations of HE4, but not of CA125, were found to be 
significantly higher in EC patients than in controls. When the analysis was limited 
to EC patients diagnosed with stage I cancer (n=32), the difference in HE4 values 
between cases and controls remained statistically significant (p<0.0001). The 
concentration of CA125 and HE4 was higher than the respective diagnostic 
thresholds in 12/46 (26%) and 27/46 (59%) EC patients. In patients with stage I 
EC, the diagnostic thresholds were exceed in 5/32 (15.6%) cases for CA125 and 
19/32 (59.3%) cases for HE4, respectively. 
Variables Endometrial cancer (n=46) 
Age, years (range) 65.0 (30-83) 
Menopausal status, n (%) 
Postmenopausal 
Premenopausal  
 
42 (91.3) 
4 (8.7) 
FIGO Stage, n (%) 
I 
II 
III-IV 
 
32 (69.6) 
7 (15.2) 
7 (15.2) 
Histological grade, n (%) 
Well- or Moderately-differentiated (G1 or G2) 
Poorly-differentiated (G3) 
 
34 (73.9) 
12 (26.1) 
CA125, U/mL (range) 
HE4, pmol/L (range) 
10.3 (0.1-624.0) 
76.6 (28.0-782.0) 
Table 1. Demographics and clinical features of endometrial cancer patients 
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. 
The serum concentration of miR-186, miR-222 and miR-223 was found to be 
significantly higher in EC patients compared to healthy controls (p=0.004, 
p=0.002 and p<0.0001, respectively), whereas that of miR-204 was significantly 
lower in cases than in controls (p<0.0001) (Figure 1). The significance of these 
differences remained unchanged when the analysis was limited to EC patients 
diagnosed with stage I cancer (p=0.002, p=0.005, p<0.0001 and p<0.0001 
respectively) (Figure 2). Interestingly, serum HE4 concentration was found to be 
higher in patients with grade 3 EC compared to those with grade 1 and 2 cancer 
(105.1 vs. 71.7 pmol/L, p=0.03), whereas the values of miRNAs and CA125 were 
virtually identical among these groups. 
The concentration of HE4 was found to be positively correlated with that of miR-
222 (r=0.36, p=0.002) or miR-223 (r=0.37, p=0.002), but also negatively 
correlated with miR-204 values (r=-0.60, p<0.0001). No significant correlation 
was instead observed between CA125 and each of the four miRNA measured in 
this study. 
The area under the curve (AUC) for identifying EC patients versus healthy 
controls was 0.70 (p=0.004) for miR-186, 0.72 (p=0.002) for miR-222, 0.88 
(p<0.0001) for miR-223 and 1.00 (p<0.0001) for miR-204, respectively (Figure 
3). When the evaluation of diagnostic performance was limited to EC patients 
diagnosed with stage I cancer, the AUC was 0.73 (p=0.002) for miR-186, 0.71 
(p=0.006) for miR-222, 0.85 (p<0.0001) for miR-223, 1.00 (p<0.0001) for miR-
204, 0.91 (p<0.0001) for HE4 and 0.55 (p=0.50) for CA125, respectively (Figure 
4). The best ROC curve-derived cut-off displayed 0.89 sensitivity and 0.79 
specificity for HE4 (40 pmol/L), 0.50 sensitivity and 0.61 specificity for CA125. 
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Figure 1. MiRNAs expression (normalized to miR-16) and HE4 and CA125 
concentrations in EC patients and healthy controls. 
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Figure 2. MiRNAs expression (normalized to miR-16) and HE4 and CA125 
concentrations in stage I EC patients and healthy controls. 
sta
ge
 
I E
C (n
=
32
)
he
alt
hy
 
co
ntr
ols
 
(n=
28
)
0.0001
0.001
0.01
0.1
p=0.0024
miR-186
m
iR
 
e
x
pr
e
s
s
io
n
 
(n
o
rm
a
liz
e
d)
sta
ge
 
I E
C (n
=
32
)
he
alt
hy
 
co
ntr
ols
 
(n=
28
)
0.001
0.01
0.1 p=0.0055
miR-222
m
iR
 
e
x
pr
e
s
s
io
n
 
(n
o
rm
a
liz
e
d)
sta
ge
 
I E
C (n
=
32
)
he
alt
hy
 
co
ntr
ols
 
(n=
28
)
0.01
0.1
1
10 p<0.0001
miR-223
m
iR
 
e
x
pr
e
s
s
io
n
 
(n
o
rm
a
liz
e
d)
sta
ge
 
I E
C (n
=
32
)
he
alt
hy
 
co
ntr
ols
 
(n=
28
)
1.0×10 -10
1.0×10 -05
1.0×1000
1.0×1005
p<0.0001
miR-204
m
iR
 
e
x
pr
e
s
s
io
n
 
(n
o
rm
a
liz
e
d)
sta
ge
 
I E
C (n
=
32
)
he
alt
hy
 
co
ntr
ols
 
(n=
28
)
0
200
400
600
800
1000
p<0.0001
HE4
HE
4,
 
pm
o
l/L
sta
ge
 
I E
C (n
=
32
)
he
alt
hy
 
co
ntr
ols
 
(n=
28
)
0
200
400
600
800
p=0.51
CA125
CA
12
5,
 
U/
m
L
 88 
 
Figure 3. MiR-186, miR-222, miR-223, miR-204, HE4 and CA125 ROC curves 
performed on EC patients and healthy controls. 
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Figure 4. MiR-186, miR-222, miR-223, miR-204, HE4 and CA125 ROC curves 
performed on stage I EC patients and healthy controls. 
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Discussion 
Despite a large number of patients with EC receive an early diagnosis (i.e., stage 
I; cancer confined to the uterus), this malignancy represents the seventh most 
common cause of death from cancer in women (21). 
Unfortunately, no single biomarker that has been tested so far exhibits diagnostic 
performance for permitting an accurate preoperative diagnosis of patients with 
early or advanced EC. In clinical practice, CA125 is broadly used for screening 
and diagnosis of EC, often in combination with diagnostic imaging and clinics. 
However, as also observed in our investigation, this biomarker is poorly sensitive 
and specific, especially in EC patients diagnosed with stage I cancer. Previous 
evidence was brought that the concentration of CA125 can be actually increased 
in up to 60% of EC patients (22), but its value was found to be above the 
diagnostic cut-off in a rather limited number of patients with stage I cancer, 
typically lower than 10% (23). In our study population the values of CA125 were 
higher than the diagnostic threshold in 15.6% of patients diagnosed with stage I 
EC, and this finding is in absolute agreement with data previously published by 
Beck et al., who also showed that CA125 was elevated above 35 U/ml in 15.2% of 
patients diagnosed with cancer at this stage (24). Interestingly, HE4 seemingly 
exhibits a much greater diagnostic sensitivity than CA125 for early diagnosis of 
EC. In agreement with data previously published by Liu et al. (7), we found that 
the values of this biomarker were increased above the optimal cut-off in more 
than half (i.e., 59%) of patients with early stage EC. Even more importantly, we 
observed that serum HE4 values were significantly higher in patients with 
advanced disease (grade 3) compared to those with low or intermediate grades. 
This is indeed a valuable finding considering that the grade was shown to be as 
important as the stage for the prognosis of this type of cancer (21). Another 
interesting finding emerged from our study is that the serum concentrations of 
CA125 and HE4, two traditional biomarkers of gynaecological malignancies, 
were not significantly intercorrelated, contrarily to what has been earlier described 
in patients with ovarian cancer (25). This is not really surprising because HE4 has 
been previously found to be a much more sensitive biomarker in the early stage of 
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endometrioid adenocarcinoma, whereas the serum value of CA125 only increases 
over the diagnostic cut-off in advanced cancer stages (26). 
The most interesting information was obtained from analysis of four candidate 
miRNAs. Interestingly, each of these small non-coding RNA molecules 
efficiently distinguished patients with EC from the control population, displaying 
an overall accuracy that was comparable (for miR-222) or even better (for miR-
204) than that of HE4. These findings are in agreement with those previously 
published by Jia et al. (18), who also studied 26 patients with EC and 22 healthy 
controls, and reported that the AUCs of the four miRNAs were between 0.73 and 
0.87, thus much better than that of CA125 (i.e., AUC 0.67). Moreover, the AUC 
was 0.93 (specificity: 87.5%, sensitivity: 91.7%) by combining the four miRNAs 
(miR-panel).  
At variance with our results, however, Jia et al. (18) found that miR-204 was 
over-expressed in this type of cancer. This is a contradictory and somehow 
inexplicable finding, wherein miR-204 is a potent suppressor of tumour growth 
and metastases, the concentration of which has been reported to be down-
regulated in various types of malignancy, including renal, brain, ovary, 
hematological and colon cancers (27). Different results could be attributed to 
differences in patients’ characteristics or methods used in the two studies. 
Accordingly, in our study women affected by EC were older (mean age: 64.3 vs. 
55.5 years) and a greater number were in a postmenopausal state (91.3% vs. 
73.1%) compared to the patients enrolled in the study of Jia and colleagues (18). 
Moreover, in our population were also included EC patients with advanced stages 
of cancer (III and IV).  
In addition, while in our study we measured the relative expression level of each 
miR normalized to miR-16, by using the 2-∆Ct method (20), in the study of Jia et 
al. (18) the authors calculated the absolute concentrations of the target miRNAs 
by using calibration curves. 
The selection and validation of endogenous controls for microRNA expression 
studies remains controversial. A down-regulation of miR-16 has been reported in 
some cancer, as chronic lymphocytic lymphoma (CLL), pituitary adenomas, and 
prostate carcinoma (28). However, several other studies performed in different 
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tumors, including gynecological cancer (29) have demonstrated that miR-16 is 
presented in plasma/serum at similar levels across normal controls and patients. 
To the best of our knowledge, no study has demonstrated that miR-16 is 
dysregulated (up- or down-) in endometrial cancer. Moreover, we found no 
differences in miR-16 Ct values between EC and healthy controls patients by 
using the same RNA concentrations. 
The complex biological pathways involving the role of the four miRNAs that we 
have investigated have not been completely elucidated so far. Nevertheless, it has 
been hypothesized that miR-186 may consistently reduce the expression of tumor 
suppressor FOXO1, and thereby deregulates cell cycle control, by direct binding 
the 3'-untranslated region of FOXO1 transcripts (30). Both miR-221 and miR-222 
are over-expressed in the majority of epithelial tumors, and they were found to 
play a tumor-suppressive role in erythroleukemic cells (31). Specifically, the miR-
221/222 system is seemingly involved in cell growth and proliferation due to its 
effect on the cyclin-dependent kinase inhibitor p27Kip1 (32), a cell cycle 
regulatory protein. Recent evidence also suggests that miR-222 acts as oncomiR 
in other cancer types through activation of the phosphoinositide 3-kinase/v-akt 
murine thymoma viral oncogene (PI3K/AKT) signaling pathway (33). 
Despite the limited number of subjects included in this study, our preliminary 
findings underpin that the assessment of CA125 is virtually meaningless in EC 
diagnostics, whereas the measurement of both HE4 and some circulating 
epigenetic biomarkers, especially miR-204, may open new avenues for early 
identification and management of patients with EC. Indeed, the greatest advantage 
of measuring serum miRNAs is that the so-called liquid biopsy is a more 
practical, accessible and inexpensive approach for investigating solid cancers than 
conventional tissue biopsies (34). At variance with traditional serum cancer 
biomarkers, miRNAs are also released in larger amounts from tumor cells into the 
circulation, so that their serum or plasma concentrations more accurately mirror 
tumor development and progression (35). In this perspective, miRNAs assessment 
may be regarded as an accurate measure for identifying patients at increased risk 
of relapse, but they may also represent putative targets for innovative therapies 
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specifically tailored to suppress oncogenes expression or enhance the activity of 
tumor suppressor genes in patients with EC or other malignancies (36).  
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4. GENERAL CONCLUSIONS 
In recent decades, the role of epigenetic alterations in carcinogenesis has received 
greater attention more than ever before. After elucidating the fundamental role of 
epigenetic changes in human carcinogenesis, considerable efforts have been 
devoted to the development of epigenetic biomarkers. 
Our results reported here indicate that circulating nucleic acids are a potentially 
promising source of tumor-specific biomarkers in patients with cancer of various 
grades and stages.  
The development of molecular techniques has opened up the potential of utilizing 
circulating nucleic acids as prospective cancer biomarkers. 
This approach may also provide personalized identification of tumor-specific 
biomarkers in serum samples once genetic and epigenetic aberrations have been 
characterized in the tumor specimen. We have demonstrated that these circulating 
tumor-specific biomarkers can be detected at any time during the course of the 
disease and once detected indicate that a tumor is probably present. 
Undoubtedly, the diagnostic value of epigenetic molecules in panels or in 
combination with the conventional clinical biomarkers could be superior to 
individual markers. 
The biggest challenge is to standardize the methodologies including sample 
storage and DNA or microRNAs extraction to translate the quantitation of 
circulating epigenetic biomarkers into a clinical routine for cancer diagnosis and 
prognosis prediction. 
 
